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III. Summary 
 
The aim of the study was to analyze the recruitment and accumulation of MDSC in the tumor 
microenvironment via C-C chemokine receptor type 5 (CCR5)/CRR5 ligand interaction, as well 
as immunosuppressive activity of CCR5-expressing tumor-infiltrating MDSC. We 
demonstrated that CCR5+ Mo-MDSC and CCR5+ Gr-MDSC accumulated during tumor 
progression in melanoma lesions of ret transgenic mice, as well as in melanoma patients at 
different stages. In the mouse model, the frequency of CCR5+ cells was higher among 
Gr-MDSC than among Mo-MDSC, whereas in melanoma patients, Mo-MDSC were 
characterized by higher frequency of CCR5+ cells. CCR5+ MDSC demonstrated an increased 
immunosuppressive phenotype reflected by enhanced NO and ROS production, as well as 
ARG-1 and PD-L1 expression, as compared to their CCR5- counterpart. Both in mouse model 
and in melanoma patients, the concentration of CCR5 ligands such as CCL3 (MIP-1α), CCL4 
(MIP-1β) and CCL5 (RANTES) and inflammatory factors such as granulocyte/macrophage 
colony-stimulating factor (GM-CSF), vascular endothelial growth factor (VEGF), interleukin 
(IL)-6 and interferon-γ (IFN-γ) were increased in skin tumors as compared to the serum that 
allows the migration of these cells to the tumor microenvironment. Furthermore, we 
demonstrated that CCR5+ MDSC inhibited T cell proliferation in a dose-dependent manner and 
showed a tendency to stronger inhibition of T cell proliferation than their CCR5- counterparts. 
In addition, we detected the CCR5 expression on CD4+ and CD8+ T cells in ret transgenic 
melanoma bearing mice. Interestingly, the frequency of CCR5+ regulatory T cells (Treg) was 
significantly higher than that among other T cell subsets. Antigen-experienced CCR5+ Treg 
accumulated in advanced stage melanoma patients as compared to early stage patients and 
healthy donor (HD). After intraperitoneal injection of mCCR5-Ig, which blocks CCR5-CCR5 
ligand interactions into tumor bearing mice, we observed a significantly increase in mouse 
survival as compared to the control group. Moreover, the frequency of MDSC and Treg 
decreased in skin tumors after mCCR5-Ig therapy. NO production by MDSC in skin tumors 
and the frequency of CD69 expression, reduced activated Treg in metastatic lymph nodes 
(LN), which indicates the therapeutic effect of mCCR5-Ig. 
In summary, we demonstrated that during melanoma progression, CCR5 expressing MDSC 
accumulated in the tumor microenvironment and exerted strong immunosuppressive activity. 
This accumulation was mediated by CCR5 ligands and other inflammatory factors. Blockage 
of CCR5-CCR5 ligand interactions induced the prolongation of the survival of tumor bearing 
mice mediated by a reduced migration and immunosuppressive activity of MDSC and Treg at 
the tumor site. Our findings define a critical role for CCR5 in recruiting MDSC and Treg, 
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which can be used for the development of novel immunotherapeutic strategies for 
melanoma patients. 
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IV. Zusammenfassung 
 
Das Ziel der Studie bestand darin, die Rekrutierung und Akkumulierung der MDSC in das 
Tumormilieu über die CC-Motiv-Chemokin-Rezeptor 5 (CCR5)/CCR5 Liganden Interaktion 
und der immunsuppressiven Aktivität der CCR5-exprimierenden, tumor-infiltrierenden MDSC 
zu analysieren. Unsere Untersuchungen zeigten, dass CCR5+ Mo-MDSC und CCR5+ 
Gr-MDSC in den Melanomläsionen der ret transgenen Mäuse sowie in Melanompatienten 
unterschiedlicher Stadien während der Tumorprogression akkumulieren. Die Anzahl der 
CCR5+ Zellen war im Mausmodel unter Gr-MDSC höher also unter Mo-MDSC, wohingegen 
Mo-MDSC in Melanompatienten eine höhere Anzahl an CCR5+ Zellen aufwiesen. CCR5+ 
MDSC zeigten einen stärkeren immun-suppressiven Phänotyp, der sich im Vergleich zu ihrem 
CCR5- Gegenpart durch eine erhöhte ROS und NOS Produktion sowie ARG-1 und PD-L1 
Expression auszeichnete. Sowohl im Mausmodel als auch in den Melanompatienten waren 
die Konzentrationen der CCR5 Liganden CCL3 (MIP-1α), CCL4 (MIP-1β) und CCL5 
(RANTES), sowie die Inflammationsfaktoren granulocyte/macrophage colony-stimulating 
factor (GM-CSF), vascular endothelial growth factor (VEGF), interleukin (IL)-6 und interferon-γ 
(IFN-γ), welche die Migration dieser Zellen ins Tumormilieu ermöglichen, in Hauttumoren 
höher als im Serum. Weiterhin war zu beobachten, dass CCR5+ MDSC die Proliferation der 
T Zellen zellzahl-abhängig blockieren und die T Zell Proliferation stärker inhibieren als ihr 
CCR5- Gegenpart. Des Weiteren wurde die CCR5 Expression auf CD4+ und CD8+ T Zellen in 
ret transgenen Melanom-tragenden Mäusen untersucht. Interessanterweise war die Anzahl an 
CCR5+ regulatorischen T Zellen (Treg) signifikant höher als bei anderen T Zell Subtypen. 
Antigen-erfahrene CCR5+ Treg akkumulierten in Melanompatienten fortgeschrittenen 
Stadiums im Vergleich zu Melanompatienten der frühen Phase und gesunden Spendern. Nach 
intraperitonealer Injektion des mCCR5-Ig, welches die CCR5-CCR5 Liganden Interaktion in 
Tumor-tragenden Mäusen blockiert, war bei den Mäusen im Vergleich zur Kontrollgruppe eine 
signifikant verlängerte Überlebensrate zu beobachten. Außerdem war die Anzahl an MDSC 
und Treg im Hauttumor nach der mCCR5-Ig Therapie geringer. Die NO Produktion der MDSC 
im Hauttumor und die Anzahl der CD69 exprimierenden, aktivierten Treg waren in den 
metastatischen Lymphknoten vermindert, was auf den therapeutischen Effekt von mCCR5-Ig 
hinweist.  
Zusammenfassend wurde gezeigt, dass während der Melanom Progression 
CCR5-exprimierender MDSC im Tumormilieu akkumulieren und eine starke 
immunsuppressive Aktivität ausüben. Diese Akkumulierung wurde durch CCR5 Liganden und 
andere Inflammationsfaktoren vermittelt. Die Blockierung der CCR5-CCR5 Liganden 
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Interaktion verlängerte das Überleben der Tumor-tragenden Mäuse, welches durch eine 
geringere Migration und immunsuppressorische Aktivität der MDSC und Treg im Tumor 
einherging. Unsere Ergebnisse deuten darauf hin, dass CCR5 eine entscheidende Rolle bei 
der Rekrutierung von MDSC und Treg spielt, welche für die Entwicklung neuer 
immuntherapeutischer Strategien an Melanompatienten verwendet werden könnte. 
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1 Introduction 
1.1 Immune system 
The immune system consists of cells, tissues and organs and is responsible for the protection 
against various foreign pathogens like viruses, bacteria, fungi, parasites and tumors. It 
distinguishes between self and non-self or altered self-structures on cells. Therefore, the 
defense mechanism of the immune system is based on detecting structural features of the 
invading pathogens. It recognizes, attacks and kills pathogens. Pathogens can thereby adapt 
in order to escape the immune system. Some parts of the immune system also play a role in 
the cases of auto-immune and cancer diseases, as well as allergy (Murphy et al., 2009). In 
vertebrates, there are two arms of the immune system: innate immune system, which is 
responsible for a broad spectrum of unspecific, pathogen structures, and adaptive immune 
system, which is specific for particular non-self-antigens (Alberts et al., 2015).  
1.1.1 Innate immune system 
The innate immune system is hereditary and serves as the first-line defense against pathogens 
with the epithelial barrier. This part of the immune system does not need a sensitization to 
antigens. The innate immune system consists of granulocytes, macrophages, dendritic cells 
(DC), natural killer (NK) cells and plasma proteins called the complement system.  
The recognition of an infectious agent is based on germline-encoded receptors. These 
receptors are called pattern recognition receptors (PRR) and recognize pathogen-associated 
molecular patterns (PAMPS). These PAMPS are conserved repeating patterns from 
microorganisms, e.g. lipopolysaccharide (LPS) of gram negative bacteria, lipoteichoic acid 
(LTA) of gram-positive bacteria, mannose and glycan of fungi, bacterial CpG DNA or double-
stranded viral RNA (Mogensen, 2009). The best characterized PRRs are toll-like receptors 
(TLR). Their activation leads to pathogen uptake by phagocytic cells. As a result of the uptake, 
the phagocytic cells secret pro-inflammatory cytokines and chemokines which are important 
for the recruitment of other immune cells (Kawai and Akira, 2010). The most efficient 
phagocytic cells are DCs. After pathogen uptake, they mature, migrate to the local lymph nodes 
(LN), where they secret factors that are important for the innate immune system and induce 
the adaptive immune response (Murphy et al., 2009). In such way they connect the innate and 
adaptive immune systems.  
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1.1.2 Adaptive immune system 
The adaptive immune system needs to be activated by the innate immune system. It is 
classified in cellular and humoral immunity. Cellular immunity consists of T cells with antigen-
specific T cell receptors (TCR) that recognize short antigen fragments bound to MHC 
molecules. The humoral immunity consists of B cells which express antigen-specific receptors 
that recognize antigenic determinants. The receptors of T cells and B cells are random 
products of somatic gene rearrangement during maturation (Murphy et al., 2009). 
Extracellular pathogens are recognized by B cells that originate from the bone marrow (BM). 
During maturation, they express membrane-bound immunoglobulins (B cell receptor, BCR). 
After activation, they differentiate into either memory or antibody-secreting plasma cells.  
Intracellular pathogens are detected by T cells via cell-mediated immune response. T cells are 
generated in the BM and migrate to the thymus for their maturation. Their TCRs recognize 
peptides only when they are presented by MHC molecules. When they bind to MHC class I, 
they are CD8+ T cells, whereas CD4+ T cells bind to MHC class II. For the complete activation, 
T cells need costimulatory signals from antigen-presenting cells (APC). After elimination of 
their targets, effector cells undergo apoptosis or build up the immunological memory that is 
responsible for a rapid reinduction of memory cells after the reentering of the same pathogen. 
This immunological memory mediates a long lasting protection against diseases (Murphy et 
al., 2009).  
1.1.2.1 T cells  
Hematopoietic precursors of T cells are generated in the bone marrow (BM) and migrate to the 
thymus, where they mature into naïve T cells. Through somatic recombination naïve T cells 
get TCR for specific antigens for a huge variety of peptide-major histocompatibility complex 
(MHC) complexes (Murphy et al., 2009). They become activated upon their stimulation with 
tumor-associated antigens presented by APC like DC, macrophages and B cells. In general, 
APC take up, process and present tumor antigens to T cells in the context of MHC class I or 
class II. In the thymus, T cells specific for endogenous MHC molecules are separated from 
cells that bind self-antigens. Afterwards, antigen-experienced T cells are capable of directly 
recognizing antigens bound to MHC molecules on tumor cells. T cells can be divided into CD4+ 
and CD8+ T cells for effective immune response (Murphy et al., 2009).  
The activation of antigen-specific T cells leads to their clonal expansion and gain the effector 
function of cytotoxic T cells. These cells specifically eliminate their target cells, in addition to 
include cancer cells. It comes to a dysfunction of these cells during prolonged antigen 
exposure. Then T cells are not able to proliferate anymore and fail to eliminate target cells 
(Murphy et al., 2009). 
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CD4+ T helper cells are responsible for the cytokine-mediated activation of the humoral 
response and for the prolonged function of the cytotoxic CD8+ T cell response. The first 
classification divided CD4+ T cells into two subsets; type 1 T helper cells (Th1) and type 2 
T helper cells (Th2) (Mosmann et al., 1986). After binding to the peptide-MHC II complex on 
APC, Th1 cells produce interferon-γ (IFN-γ) and activate the cellular immunity against 
intracellular microorganisms. Th2 cells secret interleukin (IL)-4, IL-5 and IL-13, which promote 
humoral immune response against extracellular pathogens (Zhou et al., 2009).  
Cytotoxic T lymphocytes (CTL) are responsible for the elimination of damaged or infected cells. 
After binding to the peptide-MHC I complex on APC, CTL secret perforin and granzymes and 
induce apoptosis in target cells. After completing this function the CLT undergo cell death. 
Remarkably, some of them survive and persist as memory T cells, reacting quicker upon 
reinduction with the same antigen as compared to the first antigen contact and providing long-
term immunity. Memory T cells are divided into resident memory (TRM), effector memory (TEM) 
and central memory (TCM) T cells according to their localization, their recall ability and effector 
functions (Laidlaw et al., 2016).  
1.1.2.1.1 Regulatory T cells (Treg) 
Treg were described in 1995 independently by Sakaguchi et al. (Sakaguchi et al., 1995) and 
Shevach (Bonomo et al., 1995). Treg are characterized by the expression of the transcription 
factor forkhead-box-protein P3 (FoxP3) and the IL-2 receptor α-chain (CD25). FoxP3 is a 
member of the forkhead family of deoxyribonucleic acid (DNA)-binding transcription factors 
that are required for Treg development, maintenance and function (Fontenot et al., 2003; 
Ziegler, 2006). Treg can suppress the activity of other cell types like CD4+, CD8+ T cells, DC, 
B cells, monocytes/macrophages and DC (Schmidt et al., 2012). They maintain peripheral 
tolerance, prevent autoimmune diseases and limit chronic inflammatory diseases (Vignali et 
al., 2008). There are various mechanisms of Treg-mediated suppression (Fig. 1).  
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Treg produce inhibitory cytokines such as transforming growth factor β (TGF-β) and IL-10. 
They can directly induce cytolysis in granzyme A/B or perforin-dependent manner. 
Furthermore, Treg express CD25 and thus compete with effector T cells (Teff) for IL-2. The 
deprivation of IL-2 hampers Teff in their proliferation. The expression of the inhibitory 
co-receptor cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) on Treg and the binding of 
this molecule with the co-stimulatory molecules B7-1 (CD80) and B7-2 (CD86) on DC results 
in an upregulation of indolamin-2,3-dioxygenase (IDO), which inhibits T cell activation and 
function (Vignali et al., 2008).  
Two populations of Tregs are known: natural Treg (nTreg) and adaptive or induced Treg 
(iTreg). At the moment, there are no specific markers to distinguish between the two subsets. 
nTreg development is promoted by self-peptide-MHC interaction in the thymus, independent 
of DC during T lymphocyte development (Stritesky et al., 2012). These Treg enter then in the 
peripheral circulation and distribute in peripheral reservoirs like LN and the spleen (Toda and 
Piccirillo, 2006). The conversion of naïve T cells into iTreg occurs in peripheral lymphoid 
Figure 1: Suppression mechanisms of Treg: a) suppression by inhibitory cytokines, b) suppression by cytolysis, 
c) suppression by metabolic disruption and d) suppression by modulation of DC maturation or function (Vignali et 
al., 2008). 
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organs by interactions with DC under the influence of inductive signals such as TGF-β and 
IL-10 (Toda and Piccirillo, 2006; Pletinckx et al., 2011). 
Several publications show that Treg are important pro-tumorigenic cells in the tumor 
microenvironment that inhibit anti-tumor immunity and correlate with reduced overall survival 
(Quail and Joyce, 2013). T cells with regulatory function in patients with cancer were first 
reported in 2001 (Woo et al., 2001). In this study, they found an elevated frequency of Treg in 
patients suffering from lung or ovarian cancer. The depletion of Treg leads to an improved anti-
tumor response in tumor-bearing mice (Nishikawa and Sakaguchi, 2010), but mice that lack 
FoxP3 due to a loss-of-function mutation die of multi-organ autoimmune reactions very early 
(Josefowicz et al., 2012). 
 
1.2 The immune system and cancer immunoediting 
The process of immunoediting is composed of three phases: elimination, equilibrium and 
escape. In the first phase, immune cells fight against arising tumors. The tumor is either 
eradicated or persists and enters equilibrium. The second phase is the stage of immune-
mediated latency. The cancer and immune cells stay in balance. Incomplete tumor destruction 
and escape result in an immune resistant tumor growth. When the tumor increases and 
metastasis develop, the escape phase is reached (Dunn et al., 2002). Mostly, the tumor 
escapes one or both arms of the immune system. In 2011, a new hallmark of cancer “Avoiding 
of immune destruction” by Hanahan and Weinberg emerged (Hanahan and Weinberg, 2011). 
There are several mechanisms for how tumors escape from the immune system. One of them 
is dealt with the recruitment of immunosuppressive cells such as myeloid-derived suppressor 
cells (MDSC) or Treg to the tumor microenvironment, which can affect the anti-tumor immune 
response. 
 
1.3 MDSC 
The reason why immunotherapeutic clinical studies often fail is that the tumors build up an 
immunosuppressive microenvironment to escape the immune response and to create an 
immunosuppressive network that negatively influences the immunotherapy. T cells, for 
example, are able to infiltrate into the site of a tumor but they are often unable to attack cancer 
cells. This is due to the fact that tumor cells downregulate specific antigens or MHC molecules 
and secret inhibitory molecules (Vinay et al., 2015). Furthermore, myeloid precursor cells are 
converted into MDSC in the tumor microenvironment (Talmadge and Gabrilovich, 2013). 
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MDSC represent a heterogeneous population of immature myeloid cells (IMC). They were first 
described more than 25 years ago in mice with cancer. Only some years ago, MDSC 
contribution to the negative regulation of immune responses during pathological conditions 
was demonstrated (Talmadge and Gabrilovich, 2013). All MDSC have in common their myeloid 
origin, the immature state and their ability to suppress T cell responses.  
1.3.1 Ontogeny of MDSC 
Hematopoietic stem cells differentiate in the BM via common myeloid progenitor cells into IMC. 
In healthy individuals, IMC are released in the peripheral blood and migrate to peripheral 
lymphoid organs, where they mature into macrophages, DC or granulocytes. Different 
pathological conditions, including cancer, chronic inflammation, trauma or autoimmune 
disorders can inhibit the differentiation of IMC and promote the expansion of this population. 
Subsequently, IMCs become activated by tumor-derived factors and cytokines, which lead to 
the generation of MDSC with potent immunosuppressive potential (Lindau et al., 2013).  
 
 
 
 
Figure 1: Generation and accumulation of MDSC. IMC are generated in the BM. Under healthy 
conditions, they differentiate into macrophages, DC and granulocytes. During infection, trauma or 
cancer, several cytokines are secreted. The differentiation of IMC is partially blocked and MDSC are 
accumulated and migrated to the site of inflammation, where they exert immunosuppressive functions 
(Gabrilovich and Nagaraj, 2009). 
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1.3.2 MDSC subsets in mice 
Mouse MDSC are characterized by the coexpression of CD11b and the lineage differentiation 
antigen Gr-1 (Stromnes et al., 2014). Gr-1 contains the Ly6C and Ly6G epitopes, which enable 
differentiation between two morphological and functional distinct MDSC subpopulations: 
monocytic MDSC (CD11b+Ly6ChighLy6G-) with monocytic phenotype and granulocytic MDSC 
(CD11b+Ly6ClowLy6G+) that morphologically resemble polymorphonuclear granulocytes (Youn 
et al., 2008; Zhou et al., 2010; Monu and Frey, 2012; Stromnes et al., 2014). CD11b+Gr-1+ 
monocytic and granulocytic (polymorphonuclear) subsets have been found in mice. Both 
subsets are able to inhibit T cells; however, MDSC have more potent suppressive activity in 
tumor than in peripheral lymphoid organs (Kumar et al., 2016). Studies in tumor-bearing mice 
have shown that MDSC inhibit T cell function and stimulate the development of Treg in an 
IFN-γ and IL-10 dependent way (Kumar et al., 2016). The frequency of MDSC subsets seems 
to be influenced by the cancer type.  
1.3.3 MDSC subsets in human 
Since Gr-1 marker is not expressed in humans, MDSC from cancer patients were 
characterized as Lin-HLA-DR-CD33+ or CD14-CD11b+CD33+ cells (Marvel and Gabrilovich, 
2015). Monocytic MDSC were characterized as CD11b+HLA-DR-/lowCD14+CD15- whereas 
granulocytic MDSC were CD11b+HLA-DR-/lowCD14-CD15+ cells (Filipazzi et al., 2012). Some 
studies defined Gr-MDSC as CD14-CD11b+ or CD33+HLA-DR- without expression of mature 
myeloid and lymphoid markers (Nagaraj and Gabrilovich, 2010; Stromnes et al., 2014). Under 
healthy conditions, the peripheral blood of healthy individuals contains 0.5 % IMC (Gabrilovich 
and Nagaraj, 2009). It has been described that patients with different cancer types possess 
about 75 % Gr-MDSC and 25 % Mo-MDSC among total MDSC (Kusmartsev et al., 2004; 
Gabrilovich and Nagaraj, 2009). It was found that the MDSC elimination with 5-fluorouracil 
(5-FU) results in an increased frequency of intratumoral CD8+ T cells (Vincent et al., 2010). 
High frequencies of Gr-MDSC correlate with poor prognosis in patients with breast or colorectal 
cancer (Solito et al., 2011; Zhang et al., 2013). The number of MDSC in cancer patients 
increased during tumor development. However, 3-4 weeks after surgical resection of the 
tumor, the frequency of these cells decreased. These findings were consistent with the fact 
that the generation of MDSC is due to the higher production of soluble factors secreted by the 
tumor, and a reduction of these cells results in an increased frequency of T cells (Jayaraman 
et al., 2012; Talmadge and Gabrilovich, 2013). 
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1.3.4 MDSC expansion and activation 
CD11b+Gr-1+ cells make up 20-30 % of cells in the BM of healthy mice. However, the spleen 
contains only 2-4 % CD11b+Gr-1+ cells, whereas in LN, they are almost absent (Gabrilovich 
and Nagaraj, 2009). Upon tumor development in mice, the frequency of MDSC increase by 
10 fold; a similar increase could be detected in the peripheral blood of patients with various 
cancer types (Ochoa et al., 2007). These immunosuppressive cells are also found in tumors 
(Marvel and Gabrilovich, 2015).  
There are several factors that influence the expansion, activation and accumulation of MDSC 
in tumors (Monu and Frey, 2012). Soluble factors, which are responsible for the expansion of 
MDSC, are mostly secreted by tumor cells and inhibit the maturation of IMC like 
prostaglandins, stem-cell factor (SCF), macrophage-stimulating factor (M-CSF), IL-6, 
granulocyte/macrophage colony-stimulating factor (GM-CSF) and vascular endothelial growth 
factor (VEGF) (Gabrilovich and Nagaraj, 2009; Stromnes et al., 2014). Most of these factors 
are inducers for the Janus kinase (JAK) and signal transducer and activator of transcription 
(STAT) 3 signaling pathway involved in the survival, proliferation and differentiation of myeloid 
progenitor cells. A permanent activation of the STAT3 pathway in myeloid progenitor cells 
leads to higher production of S100 calcium-binding protein A8 (S100A8) and S100 calcium-
binding protein A9 (S100A9), resulting in the inhibition of the differentiation and promoting of 
MDSC expansion in the spleen of tumor bearing mice (Cheng et al., 2008; Marvel and 
Gabrilovich, 2015). Since S100A8 and S100A9 play a critical role in the induction of 
inflammation and could induce MDSC expansion, these molecules connect the inflammation 
with immune suppression in cancer.  
The second group of factors stimulating MDSC is mainly produced by immune cells and 
fibroblasts such as IFN-γ, TLRs, IL-13, IL-4, TGF-β and IL-1β (Marvel and Gabrilovich, 2015). 
Without these factors, MDSC would not be able to exert their immunosuppressive function 
(Gabrilovich and Nagaraj, 2009). They induce STAT6, STAT1 and nuclear factor kappa B 
(NF-ĸB). STAT1 is activated by IFN-γ and IL-1β and leads to the upregulation of arginase 
(ARG-1) and inducible nitric oxide synthase (iNOS) expression (Marvel and Gabrilovich, 2015). 
Therefore, STAT1 deficient mice fail to suppress T cell proliferation (Kusmartsev and 
Gabrilovich, 2005). In addition, signaling via CD124 has been reported to induce STAT6, as 
well as ARG-1 and iNOS expression (Condamine and Gabrilovich, 2011). Moreover, both IL-4 
and IL-13 can upregulate ARG-1 activity in MDSC and enhance their immunosuppressive 
function (Gabrilovich and Nagaraj, 2009). 
It has been demonstrated that the recruitment of MDSC to the tumor microenvironment is 
mediated by such factors as CC-chemokine ligand (CCL)-2, chemokine (C-X-C motif) ligand 
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(CXCL)-5, CXCL8, CCL15 and CXCL12 (Kumar et al., 2016). In breast, ovarian and gastric 
human tumors, the migration of MDSC has been shown to be driven by the CCR2/CCL2 axis 
(Kumar et al., 2016). The migration of MDSC subsets into the tumor is thereby determined by 
the histology and the chemokines produced by the tumor. CCL2 and CCL5 have been reported 
to be the main chemokines for Mo-MDSC recruitment to the tumor (Kumar et al., 2016). 
Several studies indicate that tumor-infiltrating MDSC can convert into tumor-associated 
macrophages (TAM) under hypoxia in the tumor microenvironment (Schouppe et al., 2012; 
Solito et al., 2014; Kumar et al., 2016). MDSC can also skew macrophages towards an M2 
phenotype (Sinha et al., 2007; Ugel et al., 2015). Increasing numbers of TAMs is associated 
with poor prognosis in patients with lung cancer (Quatromoni and Eruslanov, 2012). High levels 
of TAM correlate with a bad prognosis in different cancer types (Gwak et al., 2015; Wang et 
al., 2015)  
It has been shown that MDSC stimulate the expansion and activation of Treg (Pan et al., 2010; 
Marvel and Gabrilovich, 2015). Treg induction is based on IL-10 and TGF-β production by 
MDSC (Ostrand-Rosenberg and Sinha, 2009). Furthermore, it was found that C-C chemokine 
receptor type 5 (CCR5) ligands produced by Mo-MDSC directly recruit Treg via CCR5/CCR5-
ligand interaction (Schlecker et al., 2012). Interestingly, in CCR5 deficient mice, the frequency 
of Treg was reduced and the tumor progression was delayed. 
Taken together, tumor burden and other pathological conditions like chronic inflammation and 
infection can accelerate the expansion and activation of MDSC due to the secretion of multiple 
inflammatory mediators.  
1.3.5 MDSC-mediated suppression of T cell function 
In addition to the morphological and phenotypical distinctions, MDSC subsets use different 
approaches to suppress anti-tumor immunity (Lindau et al., 2013; Stromnes et al., 2014) 
(Fig. 3). It was found that MDSC suppress T cell proliferation and T cell cytokine production 
through enhanced expression of ARG-1, NOS and the elevated production of reactive oxygen 
species (ROS) (Kumar et al., 2016). This is associated with the loss or reduced expression of 
the TCR ζ-chain (Baniyash, 2004), inhibition of T cell activation, inhibition of IFN-γ production 
by CD8+ T cells, blocking the development of CTL (Bronte et al., 2003; Kumar et al., 2016).  
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The suppressive activity of MDSC were first associated with the degradation of L-arginine. 
L-arginine is metabolized by iNOS leading to nitric oxide (NO) production and by ARG-1 
converting L-arginine into urea and L-ornithine. Both enzymes are highly activated in MDSC 
and lead to the suppression of T cell proliferation. When MDSC deplete L-arginine from the 
T cell microenvironment, ζ-chain expression is reduced and T cells are not able to transmit the 
required signals for their activation (Baniyash, 2004; Solito et al., 2014). NO induces T cell 
apoptosis and is responsible for the inhibition of MHC class II gene expression (Meirow et al., 
2015). 
ROS production can be detected in MDSC from tumor bearing mice, as well as in cancer 
patients (Gabrilovich et al., 2012; Lindau et al., 2013). Increased ROS production by MDSC is 
associated with an enhanced NADPH oxidase NOX2 activity (Solito et al., 2014). Peroxynitrite 
leads to the nitrosylation of the TCR of CD8+ T cells and prevents interactions with peptide-
MHC complex (Gabrilovich and Nagaraj, 2009). This leads to the inhibition of antigen-specific 
T cell responses through the downregulation of the ζ-chain expression in tumor bearing mice 
Figure 2: Suppressive effect of MDSC on immune cells. CD11b+Ly6C+Ly6G- monocytic MDSC and 
CD11b+Ly6C-Ly6G+ granulocytic MDSC use different mechanisms to suppress the immune system 
such as macrophage differentiation and Treg proliferation. Further, they affect T cells by the production 
of NO, ROS and L-arginine (De Veirman et al., 2014). 
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(Baniyash, 2004). The tumor-induced ROS production by MDSC is an important process by 
tumors to stimulate MDSC proliferation and to block differentiation into APC (Kusmartsev and 
Gabrilovich, 2003). In vitro studies showed that the inhibition of ROS in MDSC isolated from 
mice or patients inhibit the suppressive function of MDSC (Gabrilovich and Nagaraj, 2009).  
Programmed cell death protein 1 (PD-1) is a type I transmembrane protein with two known 
ligands: programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). PD-1 
is expressed on activated T cells, B cells, NK cells and DC whereas PD-L1 is expressed on 
cancer cells, Treg, MDSC, T cells, B cells and DC. Treg in melanoma bearing mice were 
described to stimulate MDSC to express PD-L1 and to produce IL-10 (Fujimura et al., 2012). 
Hypoxic conditions inside the tumor upregulate PD-L1 expression on tumor-infiltrating MDSC 
resulting in more potent suppressive activity as compared to splenic MDSC (Noman et al., 
2014).  
Moreover, MDSC have been reported to deplete cysteine from the T cell environment (Solito 
et al., 2014). Cysteine is essential for the activation, differentiation and proliferation of T cells. 
Under normal conditions, APC provide T cells with cysteine by importing cystine, converting it 
into cysteine and then exporting it with ASC transporters (Srivastava et al., 2010). MDSC 
compete with T cells for cysteine thus preventing the generation of cysteine on their own (Monu 
and Frey, 2012). This leads to the depletion of cysteine from the tumor microenvironment and 
the inhibition of T cell activation and function (Srivastava et al., 2010; Kumar et al., 2016). 
1.3.6 Therapeutic targeting of MDSC 
MDSC accumulation is correlated with tumor progression and associated with T cell 
suppression (Ugel et al., 2015). It has been demonstrated that the reduction of frequencies or 
immunosuppressive functions of MDSC in the tumor microenvironment significantly improves 
anti-tumor immunity (Umansky and Sevko, 2012; Wesolowski et al., 2013; Stromnes et al., 
2014). Several approaches were developed for targeting MDSC including:  
• Neutralization of tumor-derived factors that induce the development and expansion of 
MDSC  
• Induction of MDSC differentiation in macrophages, DC and granulocytes 
• Elimination of MDSC by chemotherapeutic drugs 
• Blockage of the suppressive function by MDSC 
• Inhibition of MDSC migration by blocking the interaction between chemokines and their 
receptors on MDSC surface 
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1.4 C-C chemokine receptor 5 
Chemokines are small 8-14 kDa chemoattractant cytokines for leukocyte trafficking to the site 
of inflammation through interactions with specific transmembrane, G protein-coupled receptors 
(GPCR). 50 endogenous chemokines binding to 20 GPCR were described (Palomino and 
Marti, 2015). A few of the chemokines bind to more than one receptor. Chemokines are known 
to be involved in inflammatory diseases and cancer. In cancer, chemokines are secreted by 
tumor cells to attract immune cells by binding onto their receptors. These receptors in general 
are members of the seven transmembrane receptors and signal through the heterotrimeric 
G proteins upon ligand binding (Jo and Jung, 2016).  
CCR5 is a member of the trimeric guanine nucleotide-binding-protein-coupled seven-
transmembrane receptor superfamily that acts via G proteins. It is composed of 352 amino 
acids and has a molecular mass of 40.6 kDa (Barmania and Pepper, 2013). The ligands of 
CCR5 named CCL3 (MIP-1α), CCL4 (MIP-1β) and CCL5 (RANTES) are secreted by tumor 
cells, T cells, monocytes/ macrophages, DC and MDSC. CCR5 is expressed on memory and 
effector T cells, monocytes, macrophages, immature DC and MDSC. Its ligands enable 
CCR5-expressing cells to migrate to the site of inflammation (Barmania and Pepper, 2013).  
1.4.1 CCR5 in HIV 
CCR5 and CXCR4 were shown to be key receptors for the entry of human immunodeficiency 
virus (HIV). Individuals exhibiting a 32 bp deletion in the CCR5 gene produce a non-functional 
protein which is not expressed on the surface. The mutated allele contains 215 amino acids in 
comparison to 352 amino acids of the wild type (WT) CCR5. The protein finally lacks the last 
three transmembrane domains and regions, which are crucial for interaction with the G-protein 
and signal transduction (Barmania and Pepper, 2013). In northern Europe, around 20 % of the 
population have a CCR5∆32 polymorphism whereas the deletion is almost absent in African, 
Middle Eastern and American Indian populations (Bryant and Slade, 2015). Homozygote 
people with a depletion of 32 bp in the CCR5 gene (∆32 mutation) do not express the receptor 
whereas heterozygotes express it partially as compared to WT homozygotes (Bhatia et al., 
2009). Individuals harboring homozygous mutant allele (∆32/∆32) are highly resistant to HIV-1 
infection, whereas heterozygotes (∆32/wt) can delay progression of HIV infection (Harper et 
al., 2015).  
It has been recently found that patients with a functional mutated CCR5 are resistant to 
prostate cancer (Balistreri et al., 2009). Moreover, it has been demonstrated that melanoma 
patients with a CCR5∆32 deletion showed a decreased overall survival following 
immunotherapy as compared to patients with WT alleles (Ugurel et al., 2008).  
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1.4.2 The role of CCR5 in cancer 
Since it was shown that CCR5 might play a role in cancer, the study of CCR5-CCR5 ligand 
axis revealed that melanoma growth is delayed in CCR5-deficient mice (Aldinucci and 
Colombatti, 2014). In a transplantable B16 melanoma model, it was found that CCR5 
expression on stromal cells is necessary for the spread of melanoma cells to the lungs (van 
Deventer et al., 2005).  
Inhibition of CCR5-CCR5 ligand interaction by maraviroc has been recently shown to delay the 
tumor growth in colorectal cancer patients, although the number of Treg was not reduced 
(Ward et al., 2015). On the other side, the CCR5 inhibitor TAL-779 blocked the migration of 
Treg to the tumor microenvironment and thereby resulted in a reduced tumor growth in the 
mouse model of pancreatic cancer (Tan et al., 2009). Furthermore, it could be shown that 
CCL5 enhances the proliferative and invasive capacity of prostate cancer cells in vitro, an 
effect which could be abolished by the CCR5 antagonist TAK-779 (Vaday et al., 2006). Another 
group found that the treatment with Met-CCL5, an antagonist of CCR5 and CCR1, decreased 
the tumor growth in a breast cancer mouse model (Robinson et al., 2003).  
CCR5 deficient mice, which were injected with B16 melanoma cells, showed a delayed tumor 
growth and a better response to cancer vaccines (Ng-Cashin et al., 2003). However, the role 
of the CCR5-CCR5 ligand interactions in MDSC accumulation in tumor microenvironment 
during melanoma progression needs to be clarified. 
 
1.5 Malignant Melanoma 
Malignant melanoma is an aggressive malignancy of transformed melanocytes that is resistant 
to standard therapy, e.g. chemo-radiotherapy. In the United States, melanoma is the fifth and 
sixth most common type of cancer in males and females expected to be diagnosed in 2016 
(Siegel et al., 2016). Only 5 % of all skin cancers account for melanoma, but it is responsible 
for 90 % of skin cancer deaths. In terms of incident, malignant melanoma is the most rapidly 
increasing malignancy in Western population (Garbe et al., 2010) due to improved life 
standard, e.g. travelling to sunny resorts and get tanned and due to the higher life average of 
the people. Mostly effected are young and middle-aged Caucasians triggered by solar UV 
radiation, fair skin, red or blond hairs, blue eyes or family history of melanoma (MacKie et al., 
2009).  
Melanoma arises from the transformation of melanin-producing melanocytes in the skin and 
rarely in non-cutaneous melanocytes like retina or mucosal surfaces. Patients suffering from 
melanoma can be divided into different groups according to the TNM classification. This 
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classification considers the size of the tumor, the affection of LN and metastasis (Garbe et al., 
2010). Stage I is an invasive melanoma and tumor cells spread in situ. In stage II, when the 
tumor size is 1.5 mm or bigger, patients have a 5-year survival rate of 45-79%. When the tumor 
starts to metastasize into regional LN and the skin, patients are in stage III. Stage IV is 
classified when the tumor cells from distant metastases spread through the peripheral blood, 
and lymphatic system into the brain, lung, liver skin and BM.  
There are some gene mutations involved in melanoma development. In almost 80 % of 
melanoma cases, the BRAF or NRAS gene is mutated which are important for the MAP-kinase 
signaling pathway (Bertolotto, 2013). Mutations in these genes promote the proliferation of 
melanoma cells.  
 
1.6 Melanoma therapy 
1.6.1 Conventional therapy 
The standard procedure for localized melanoma with adequate margins is surgical excision 
and the assessment of metastasis with short-term and long-term fellow-ups (Koshenkov et al., 
2016). Patients with non-resectable metastasis or advanced melanoma are treated with 
radiotherapy (Davar and Kirkwood, 2016). This method is still in use after tumor dissection to 
treat left tumor tissue. Conventional chemotherapeutics such as dacarbazin and temozolomid 
were shown not to have a significant increase in the overall survival of patients and the number 
of responding patients was very low (Bhatia et al., 2009).  
1.6.2 Targeted therapies 
40 – 60 % of cutaneous melanoma patients have a mutation in BRAF (V600E) that 
constitutively activates the mitogen-activated protein (MAP) kinase pathway (Palmieri et al., 
2015). In 2011, vemurafinib, a BRAFV600 kinase inhibitor was approved for patients carrying 
the V600E mutation with unresectable or metastatic melanoma. The disadvantage of this 
therapy is the short-term duration of 6-8 months of clinical response and drug resistance due 
to the fast development of resistances to these drugs (Chapman et al., 2011). Since the 
approval of a BRAF inhibitor, vemurafinib is the standard therapy for patients with the BRAF 
mutation (Bertolotto, 2013). 
Recently, there has been shown an efficacy of trametinib and cobimetinib, two inhibitors of 
MEK kinase, which are located downstream of BRAF in the MAP kinase pathway. A 
combinatory therapy with BRAF and MEK inhibitors was shown to delay resistance 
development (Robert et al., 2015). 
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1.6.3 Negative checkpoint inhibitors 
CTLA-4 is expressed on T cells and competes with CD28 for the ligands CD80 and CD86 on 
APC, thereby leading to an inhibition in T cell activation. Ipilimumab is a human monoclonal 
antibody that binds to the extracellular domain of CTLA-4 and enhances T cell activation and 
function promoting anti-tumor immunity (Bhatia et al., 2009). The therapy with ipilimumab 
resulted in an increased overall survival in melanoma patients (Redman et al., 2016). 
Ipilimumab has been approved in 2011.  
PD-1 is another immune checkpoint molecule that is upregulated upon T cell activation. When 
PD-1 binds to PD-L1 (B7-H1) and PD-L2 (B7-H2), which are expressed on tumor cells and 
MDSC, T cell activity is blocked (He et al., 2015). Pembrolizumab, an antibody against PD-1, 
has been approved for the treatment of melanoma patients (Raedler, 2015). The blockage of 
the interaction between PD-1 and PD-L1 potentiates the immune response and mediates 
anti-tumor activity. 
Further development of the melanoma treatment is linked with combined therapies (Ott, 2015). 
Thus, a triple combination therapy of BRAF and MEK inhibitors and adoptive therapy in 
BRAFV600E mutant transgenic mice resulted in increased MHC I molecule expression. These 
led to increased T cell infiltration to the tumor associated with complete tumor regression (Hu-
Lieskovan et al., 2015).  
 
1.7 Ret transgenic mouse melanoma model 
In transplantable models like B16 melanoma, the interaction of the tumor cells with the immune 
system and tumor stroma is not comparable with the human situation. In contrast, in ret 
transgenic mice, melanoma develops spontaneously, resembling human melanoma with 
regards to tumor genetics, histopathology and clinical development in more detail (Kato et al., 
1998; Umansky et al., 2008). In this model, the human ret oncogene was fused with a 
methallothioneine-I promotor, leading to the overexpression of the receptor tyrosine kinase Ret 
in melanocytes. Activation of the kinase leads to the activation of downstream signaling 
molecules like mitogen-activated protein kinase (MAPK), Erk2 and c-Jun. The activation of Ret 
kinase promotes malignant transformation of melanocytes and tumor development. Melanoma 
emerges at the head, neck, back, and tail and metastasizes in LN, BM, liver, brain and lungs 
(Sevko et al., 2013). Melanoma lesions show characteristic melanoma morphology and 
express melanoma-associated antigens like S100, tyrosinase, tyrosinase related protein 
(TRP)-1, TRP-2 and gp100 (Abschuetz et al., 2012). The metastatic profile is similar to the 
metastatic pattern in patients with malignant melanoma (Houghton and Polsky, 2002). 
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Although the mutation of ret has not been detected in melanoma patients, the activation of the 
MAP-kinase signaling pathway is routinely seen in human melanoma (Sullivan and Flaherty, 
2013).  
It was previously shown that immunosuppressive cells like MDSC and Treg accumulate during 
tumor progression in skin tumors and metastatic LN (Kimpfler et al., 2009; Sevko et al., 2013). 
Furthermore, MDSC were described to inhibit T cell response, which allows a rapid tumor 
progression and metastasis (Umansky and Sevko, 2012). Administration of the 
phosphodiesterase-5 inhibitor, sildenafil, neutralizes the MDSC immunosuppressive activity, 
which leads then to the increased survival of melanoma-bearing mice. Furthermore, various 
factors that drive MDSC activation, expansion and migration were found at the site of tumor 
(Meyer et al., 2011; Umansky and Sevko, 2012). This complex immunosuppressive network 
in the tumor microenvironment could be a reason that conventional melanoma therapies are 
not successful and novel strategies have to be found. We propose to block the CCR5-CCR5 
ligand interactions by mCCR5-Ig that binds and neutralizes CCL3, CCL4 and CCL5 thus 
inhibiting MDSC and Treg infiltration into the site of tumor, restoring T cell activity and finally 
prolonging the survival of mice. 
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2 Aim of the project 
 
Patients with malignant melanoma have bad prognosis once the tumor has metastasized due 
to a chronic inflammation that induces strong immunosuppression. The investigation of novel 
therapeutic strategies is therefore very important. MDSC represent a heterogeneous 
population of immature macrophages, granulocytes or dendritic cells (DC) that accumulate 
during tumor development in cancer patients and in tumor bearing mice. CCR5 is a chemokine 
receptor that binds to its ligands CCL3 (MIP-1α), CCL4 (MIP-1β) and CCL5 (RANTES). Since 
CCR5 is reported to induce tumor growth, angiogenesis, metastasis and immune evasion, 
several CCR5 antagonists are already used to boost anti-tumor immune response.  
The aim of the study was to characterize the recruitment and migration of human and mouse 
CCR5 expressing MDSC to the site of inflammation (melanoma lesions) and to investigate 
their phenotype and immunosuppressive activity in the tumor microenvironment. We studied 
the levels of factors inducing MDSC migration in melanoma lesions of ret transgenic mice and 
melanoma patients. In order to analyze the phenotype of CCR5+ MDSC, immunosuppressive 
molecules such as ROS, NO, ARG-1 and PD-L1 were measured in ret transgenic tumor 
bearing mice and in peripheral blood from melanoma patients at different stages. Furthermore, 
we compared the immunosuppressive activity of CCR5+ MDSC and their CCR5- counterparts. 
Since CCR5 is also known to be expressed on T cells, we investigated the CCR5 expression 
on various T cell subsets focusing on Treg, which displayed an immunosuppressive function. 
Based on targeting of CCR5-CCR5 ligand interaction to block the MDSC recruitment, we aimed 
to evaluate the possibility of neutralizing immunosuppression in the tumor microenvironment 
with the mCCR5-Ig fusion protein in vivo. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Mouse strains 
3.1.1.1 Spontaneous ret transgenic mouse melanoma model 
Mice (C57BL/6 background) expressing the human ret transgene in melanocytes under the 
control of mouse metallothionein-I promotor-enhancer were provided by Dr. I. Nakashima 
(Chubu University, Aichi, Japan) (Kato et al., 1998). These mice overexpress the human Ret 
proto-oncogene in melanocytes under the control of mouse metallothionein-I 
promoter-enhancer. The tumor develops spontaneously approximately 40 day after birth. 
Every second day the mice were monitored. As controls, mice without a macroscopically visible 
tumor and non-transgenic WT were used.  
Mice were crossed and kept under pathogen-free conditions in the animal facility of the 
German Cancer Research Center (Heidelberg, Germany). Experiments were performed in 
accordance with government and institutional guidelines and regulations. 
 
3.1.2 Cell culture products 
Product Company Catalog No. 
96-well flat bottom with lid TPP® 92096 
96-well U-bottom with lid Sigma Aldrich M9436-100EA 
24-well flat bottom with lid Greiner bio-one 622160 
12-well flat bottom with lid BD 353043 
6-well flat bottom with lid Thermo Scientific 140675 
50 mL conical tubes Falcon 352070 
15 mL conical tubes Falcon 352096 
5 mL round-bottom polypropylene test tubes BD 352008 
5 mL round-bottom polypropylene test tubes w. 
cell strainer BD 352235 
serological pipettes: 5, 10 and 25 mL, sterile Greiner bio-one 606180 
607180 
760180 
40 µm cell strainer BD  
Cryovial, 2 mL sterile Sigma Aldrich V5760-500EA 
Freezing Container, "Mr. Frosty"   
Safe lock tubes: 0.5, 1.5 and 2 mL Eppendorf  
Filter tips: 20, 200, 1000 µL Steinbrenner 
SL-GPS-L10, L250, 
L1000 
Neubaur Zählkammer   
Cell culture flasks T75 Sigma Aldrich C7231-120EA 
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Syringe 1 mL BD  
LeucoSep tubes Greiner Bio-one   
 
3.1.3 Cell culture media 
Product Company Catalog No. 
HEPES Buffer (1M) Sigma Aldrich H0887 
MEM NEAA (100x) Gibco 11140-035 
UltraPure™ EDTA (0.5M, pH 8.0) Gibco 15575 
sodium pyruvate (100 mM) Gibco 11360-039 
2-βMercaptoethanol (50 mM) Gibco 31350 
RPMI Medium 1640 (1x) + GlutaMAX™ Gibco 61870-010 
DPBS (1x) Gibco 14190-094 
MEM-α Medium (1x) Gibco 22561-021 
X-Vivo 20 Lonza BE04-448Q 
Ficoll Sigma Aldrich  
Fetal Bovine Serum PAN Biotech GmbH 3702-P260718 
Bovin serum albumin Sigma 7030-50G 
Penicillin/ Streptomycin PAA P11-010 
Dimethylsulfoxid (DMSO) Merck 109678 
0.4 % Trypan blue solution Sigma Aldrich T8154 
Dimethylsulphoxide Hybrid Max (DMSO) Sigma Aldrich 472301-100ML 
MACS BSA Stock Solution (10 %) Miltenyi Biotec 130-091-376 
Dynabeads® Mouse T-Activator 
CD3/CD28 
Gibco 11453D 
 
3.1.4 Magnetic cell sorting (MACS) 
Product Company Catalog No. 
CD8+ T cell isolation kit Miltenyi Biotec 130-104-075 
Myeloid-derived Suppressor cell isolation 
kit 
Miltenyi Biotec 130-094-538 
MACS Columns 25LS Miltenyi Biotec 130-042-401 
MACS Columns 25MS Miltenyi Biotec 130-042-201 
 
3.1.5 Kits 
Product Company Catalog No. 
BCA™ Protein Assay Kit Thermo Scientific  23225 
Bio-Plex®Cell lysis kit Bio-Rad 171-304011 
Bio-Plex® TGF-β1 Set Bio-Rad 171-V4001M 
Bio-Plex® TGF-β Standard 
Bio-Plex® Pro™ Human Cytokine 27-plex 
Bio-Plex® Pro™ Mouse Cytokine 23-plex 
Bio-Rad 
Bio-Rad 
Bio-Rad 
171-X40001 
M500KCAF0Y 
M60009RDPD 
FoxP3/ Transcription Factor Fixation/ 
Permeabilisation Concentrate and Diluent 
eBioscience 00-5521-00 
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Permeabilisation Buffer (10x) eBioscience 00-8333-56 
 
3.1.6 Antibodies 
3.1.6.1 Human panel 
Primary antibodies Fluorochrom Clone Company Catalog No. 
CD11b APC ICRF44 BD 550019 
HLA-DR APC-H7 G46-6 BD 561358 
CD14 PerCp Cy5.5 MΦP9 BD 345786 
CD15 PE HI98 BD 555402 
PD-L1/ CD274 PE Cy7 MIH1 BD 558017 
CD45 PerCp Cy5.5 HI30 Biolegend 304028 
CD3 PerCp Cy5.5 HIT3a Biolegend 300328 
CD4 PE Cy7 SK3 BD 557852 
CD4 APC Cy7 RPA-T4 BD 557871 
CD45RA PE Cy7 HI100 eBioscience 25-0458-42 
CD8 APC Cy7 SK1 BD 557834 
CD25 PE M-A251 BD 555432 
CD127 FITC eBioRDR5 eBioscience 11-1278-42 
TCR/ CD247 FITC 6B10.2 Biolegend 644104 
CD8a eFluor450 53-6.7 eBioscience 48-0081-82 
CD69 PE Cy7 FN50 BD 557745 
CCR5 BV421 2D7/CCR5 BD 562578 
FoxP3 APC 236A/E7 eBioscience 17-4777-42 
 
3.1.6.2 Mouse panel 
Primary antibodies Fluorochrome Clone Company Catalog. No. 
CD11b APC Cy7 M1/70 BD 557657 
CD11b APC M1/70 BD 553312 
Gr-1 PE Cy7 RB6-8C5 BD 552985 
Ly6C FITC AL-21 BD 553104 
Ly6C APC AL-21 BD 560595 
CCR5 PE C34-3448 BD 559923 
CCR5 APC HM-CCR5 Biolegend 107012 
CCR2 APC 475301 R&D FAB5538A 
PD-L1 APC MIH5 BD 564715 
PD-L1 BV421 MIH5 BD 564716 
CD45.2 PerCp Cy5.5 1O4 BD 552950 
CD3 PerCp Cy5.5 145-2C11 BD 551163 
CD4 PE cCy7 RM4-5 BD 552775 
CD8 APC Cy7 53-6.7 BD 557654 
CD8 APC Cy7 YTS156.7.7 Biolegend 126620 
CD25 APC Cy7 PC61 Biolegend 102026 
CD25 APC PC61 BD 557192 
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FoxP3 FITC FJK-16s eBioscience 11-5773-82 
TCR/ CD247 PE K25-407.69 BD 558448 
PD-1/ CD279 BV421 J43 BD 562584 
CD69 APC H1.2F3 BD 560689 
 
3.1.6.3 Human/mouse reagents 
Primary antibodies Fluorochrome Clone Company Catalog No. 
NOS Detection Kit 
FITC-channel (488 
nm) 
production of 
chemical 
reaction 
cell technologies NOS200-2 
hROS Detection Kit cell technologies FLAPF100-2 
anti-h/m ARG-1 APC MAB58681 R&D IC5868A 
FcR Blocking Reagent     Miltenyi 130-059-901 
 
3.1.7 Chemicals and biological reagents 
Product Company Catalog No. 
7-AAD  BD 51-68981E 
recombinant murine (CCL2)   
recombinant murine MIP-1α (CCL3) Peprotech 250-09 
recombinant murine MIP-1β (CCL4) Peprotech 250-32 
recombinant murine RANTES (CCL5) Peprotech 250-07 
recombinant mouse VEGF Peprotech  
recombinant murine GM-CSF Peprotech 315-03 
recombinant murine IL-6 Peprotech 216-16 
recombinant mouse TNF-α Peprotech  
Carboxyfluorescein succinimidyl ester 
(CFSE) 
Biolegend 423801 
Heparin-Natrium-25000 Units Ratiopharm PZN-3029843 
Isofluran   
RBC Lysis Buffer (10x) Biolegend 420301 
 
3.1.8 Solutions 
Solution Ingredients 
Freezing medium 1 60 % FBS 
40 % X-VIVO 20 
Freezing medium 2 75 % FBS 
25 % DMSO 
MACS buffer 1x PBS 
1% FCS 
0.5 mM EDTA 
Materials and Methods  22 
__________________________________________________________________________ 
 
 
Primary cell culture medium 1x RPMI 
10 % FCS 
100 U/ml Penicillin, 100 µg/ml Streptamycin 
1mM Sodium pyruvate 
1x Non-essential amino acids 
0.5 mM ß-Mercaptoethanol 
FACS buffer 1x PBS 
2% FBS 
0,2 % NaN3  
2mM EDTA 
SORT buffer 0.5 M EDTA 
1 % FCS 
1 M HEPES 
in 500 ml HBSS 
 
3.1.9 Dextramers 
Product Fluorochom Allele Peptide Company Cat. No. 
MHC dextramer H-2 Kb / 
SVYDFFVWL / PE 
PE H-2 Kb SVYDFFVWL Immudex JD2199 
 
3.1.10 Routine laboratory material 
Product Company Catalog No. 
Needle (27G) neolab 194210020 
Needle (23G) BD 300800 
Needle (25G) BD 300400 
6.5 mm Transwell® with 3.0 µm Pore 
Polycarbonate Membrane Insert 
Corning 3415 
Pipets: 2-20 µL, 20-200 µL, 200-1000 µL Rainin L-20XLS+,  
L-200XLS+,  
L-1000XLS+ 
Object carrier Superfrost plus R. Langenbrinck 03-0060 
 
3.1.11 Laboratory equipment 
Equipment Name Company 
Anesthesia machine IsoFlo Vaporiser Eickemeyer 
Cell culture incubator Hera Cell Heraeus 
Centriguges 
Laborfuge 400R 
Laborfuge 40R 
Biofuge primo R 
Varifuge K 
Heraeus 
Microplate Reader Tecan infinite M200 Tecan 
Flow cytometer FACS Canto II, 8 
colours BD 
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Laminar flow hood Hera safe 
Thermo Electron 
Cooperation 
Refrigerator (-20 °C) Premium Liebherr 
Refrigerator (-80 °C) HeraFreeze Heraeus 
Fridge  Liebherr 
Ice machine   
Magnetic stirrer RCT basic IKA Werke 
Microscope DMIL Leica 
N2 tank   
pH meter 766 Calimatic 
Vortexer REAX top Heidolph 
Vortexer Vortex Genie 2 Scientific Industries 
Balance BP 3100P Sartorius 
Water bath DC3 HAAKE, GFL 
 
3.1.12 Software for data analysis 
Product Company 
Flow Jo (Version 7.6.1) Tree Star, Inc., Ashland, USA 
GraphPad PRISM (Version 5) GraphPad Software, Inc., San Diego, USA 
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3.3 Methods 
3.3.1 Determination of cell numbers 
To distinguish dead from live cells, an aliquot of cell suspension was diluted 1:10 with trypan 
blue. Cell numbers were determined by using a Neubauer counting chamber and the total 
number of cells per mL was calculated by the formula: 
(Counted cell number / number of counted chambers) x 104 x dilution factor. 
3.3.2 Organ preparation and single cell suspension from ret transgenic mice 
Mice were sacrificed by cervical dislocation for organ preparation or by asphyxiation with 
isoflurane for blood collection. 
3.3.2.1 Blood 
Peripheral blood was obtained by puncture of the caudal (inferior) vena cava with a 
heparin-wetted syringe. Per mouse, 0.5-0.8 mL blood was collected. Whole blood was 
centrifuged at 1400 rpm for 7 min and serum was frozen at -80 °C. Peripheral blood was treated 
with 1 mL lysis buffer and washed with PBS (1400 rpm, 7 min, 4 °C) to get rid of the 
erythrocytes. Pellet was resuspended in PBS for FACS analysis. 
3.3.2.2 Spleen 
Mouse spleen was collected in a 15 mL falcon tube with 5 mL PBS. Single cell suspension 
was prepared by smashing the spleen with a plunger through a 40 µm cell strainer and washing 
with PBS at 1400 rpm for 7 min. Erythrocytes were depleted with 2 mL lysis buffer followed by 
3 min of incubation at room temperature (RT). To stop the reaction, cells were washed with 
10 mL PBS before cells were counted and resuspended in medium or PBS dependent on the 
following assay. 
3.3.2.3 Bone marrow 
Femur and tibiae from the same mouse were cut at both ends. BM was flushed out with PBS 
using a syringe with a 23G needle. Cells were filtered through a 40 µm cell strainer and washed 
with PBS at 1400 rpm, for 7 min. Red blood cells were lysed with 2 mL lysis buffer for 3 min at 
RT. PBS was used to stop the reaction and cells were washed at 1400 rpm for 7 min. Pellet 
was resuspended in appropriate buffer for further analysis.  
3.3.2.4 Metastatic lymph nodes 
LN from the inguinal, axillary and head region were extracted. LN were smashed between two 
object slides and filtered through a 40 µm cell strainer. The strainer was then washed with PBS 
to collect all cells. The cells were washed with PBS at 1400 rpm, 7 min and resuspended in 
PBS for flow cytometry. 
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3.3.2.5 Skin tumor 
The isolated skin tumors from melanoma bearing mice were weight and smashed through a 
40 µm cell strainer by a plunger into a 50 mL falcon tube. After the depletion of the erythrocytes, 
cells were washed with PBS at 1400 rpm for 7 min and resuspended in an appropriate buffer 
for further analysis.  
3.3.3 Fluorescence activated cell sorting (FACS) 
Flow cytometry allows for the simultaneous, multiparametric analysis of single cells based on 
the emission of electronic light. Cells that pass the laser emit scattered light. The forward 
scatter (FSC) gives information about the size, the side scatter (SSC) measures the granularity 
of the cell. With the emitted fluorescence of the bound antibody, it is possible to analyze the 
frequency of antigen expressing cells, as well as the intensity of the expression.  
3.3.4 Surface staining 
1x106 cells were transferred into a 96-well flat-bottom plate and centrifuged at 1000 rpm for 
7 min. The supernatant was discarded and the pellet was resuspended in fluorescence-
activated cell sorting (FACS) buffer with Fc-blocking reagent for 10 min at 4 °C. Cells were 
washed with 100 µL FACS buffer and centrifuged (1000 rpm, 7 min). The pellet was stained 
with fluorochrom-conjugated monoclonal antibodies against surface antigens. After incubation 
of 30 min at 4 °C, cells were centrifuged (1000 rpm, 7 min), washed twice with 200 µL FACS 
buffer and measured with FACSCanto II (BD) using the BD Diva Software V.6.1.1. At least 
800.000 events were measured for CCR5 analysis and 20.000 events for CD8+ T cell 
proliferation. FlowJo software 7.6.1 (Tree Star) was used for dot plots or histograms. 
3.3.5 Intracellular staining 
For intracellular staining, single cell suspension was incubated in 100 µL of fixation/ 
permeabilization solution (1:4 dilution) (eBioscience) for 45 min at 4 °C and subsequently 
washed twice with 200 µL permeabilization buffer before fluorescently labeled antibodies 
against intracellular antigens were added. After 30 min incubation at 4 °C, cells were washed 
with FACS buffer, resuspended in 100 µL of the same and measured by flow cytometry 
(FACSCanto II from BD Biosciences). FlowJo software 7.6.1 (Tree Star) was used for data 
analysis and shown as dot plots and histograms. 
3.3.6 Bio-plex assay  
For the detection of multiple cytokines and chemokines in the serum and lysates of skin tumors 
and metastatic LN, bio-plex assay was performed. Bio-plex assay is based on capture of 
antibodies that are directed against particular soluble factors and conjugated with beads. The 
reaction is detected by antibodies coupled to horseradish peroxidase.   
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3.3.6.1 Preparation of skin tumor and metastatic LN lysates 
Skin tumors and metastatic LN were isolated and one small piece (3 mm²) of the tumor or LN 
was snap frozen in liquid nitrogen. To prepare lysates of the tissue, 250 µL lysis buffer for the 
tumor or 150 µL for the LN were added to the frozen samples. The tissue was mechanically 
smashed in an Eppendorf tube then frozen at -80 °C for 10 min. Lysates were thawed on ice 
and the rest of the tissue was broken down in the ultrasonic bath for 20 min at 4 °C. Lysates 
were again frozen at -80 °C for 20 min and thawed on ice before they were centrifuged at 
1300 rpm for 20 min at 4 °C. Supernatant was transferred into a new Eppendorf tube and 
protein concentration was determined by bicinchoninic acid (BCA) assay. Samples were 
diluted with bio-plex sample diluent to a concentration of 1 mg/mL total protein. Cytokine and 
chemokine concentration were finally determined with a bio-plex protein array according to the 
manufacturer´s instructions. 
3.3.6.2 Preparation of serum 
Serum was centrifuged at 13000 rpm for 10 min, 4 °C and protein concentration was measured 
by BCA assay. For the bio-plex protein array, 30 µL serum was used and the final cytokine or 
chemokine concentration was then recalculated with the total protein concentration measured 
before by Pierce BCA Protein Assay Kit. 
3.3.6.3 Procedure of the assay 
Analysis of chronic inflammatory factors (CCL2, CCL3, CCL4, CCL5, IL-1β, IL-1RA, IL-2, IL-4, 
IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL12p70, IL13, IL-15, IL17A, TGF-β, FGF-2, eotaxin, G-CSF, 
GM-CSF, IFN-γ, interferon-gamma induced protein 10 (IP-10), TNF-α, VEGF, and 
PDGF-AB/BB) in serum samples and metastasis lysates of the same melanoma patient were 
performed by the multiplex technology (Bio-Rad) according to the manufacturer´s protocol. 
Concentration of chronic inflammatory factors in serum and LN lysates of WT and ret 
transgenic mice without visible skin tumors, as well as in skin tumor lysates of ret transgenic 
tumor bearing mice, were measured by multiplex technology according to the manufacturer´s 
protocol. Bio-plex Manager™ software (Version 6.0) was used for the acquisition and data 
analysis. 
3.3.7 Proliferation Assay 
In order to analyze the immunosuppressive activity of CCR5 MDSC subsets on T cell 
proliferation, CCR5+ MDSC or CCR5- MDSC were sorted and co-cultured with CD8+ T cells 
isolated from the spleens of BL/6 mice.  
For MDSC isolation, BM from femur and tibiae of tumor bearing mice were collected and 
prepared as described in 3.2.2.3. After lysis of the erythrocytes, BM cell suspension was 
stained with anti-mouse CD11b-APC Cy7, anti-mouse Gr-1-PE Cy7 and anti-mouse CCR5-PE 
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for 30 min at 4 °C. Cell suspension was then washed with PBS at 1400 rpm for 7 min and the 
pellet was resuspended with SORT-buffer. CCR5+ and CCR5- subsets of CD11b+Gr1+ MDSC 
were sorted using FACSAria cell sorter (BD Biosciences). The purity of sorted cell populations 
was 99%. 
For the isolation of T cells, the spleen of one WT mouse was isolated and single cell 
suspension was prepared. Pellet was resuspended in PBS and cells were counted by 
Neubauer counting chamber. The cell suspension was centrifuged at 1400 rpm for 7 min and 
the pellet was resuspended in MACS buffer according to the provided MACS protocol to isolate 
CD8+ T cells. For the detection of proliferating T cells, the cell suspension was centrifuged at 
1400 rpm for 7 min and the pellet was stained with 1 µM CFSE for 5 min at 37 °C in the water 
bath. The reaction was stopped by adding 10 mL MDSC complete medium. Cells were 
centrifuged at 1400 rpm for 7 min and the pellet was resuspended in MDSC complete medium 
to count the cells by Neubauer counting chamber. 
For co-culturing, 2x104 CD8+ T cells and the appropriate amount of CCR5+ or CCR5- MDSC 
were cultivated in 96 U-bottom well plates in MDSC complete medium. For T cell activation, 
Dynabeads® magnetic beads at a bead-to-T cell ratio of 1:1 were prepared according to the 
Dynabeads® mouse T-activator CD3/CD28 kit protocol and added to the co-culture. MDSC 
activation and proliferation was ensured by adding 40 ng/mL GM-CSF and 40 ng/mL IL-6 
(peproTech) to the culture. After 3 days of co-culture at 37 °C, 5 % CO2 and 95 % humidity, 
cells were pelleted. Cells were stained with anti-mouse CD8-eFluor450 antibodies to identify 
CD8+ T cells by flow cytometry. 
3.3.8 MHC dextramer staining of TRP-2 specific CD8+ T cells 
Dextramer® Technology is based on the interaction of TCR on T cells and MHC complex on 
APC. Fluorescent labeled MHC dextramers enables the detection of antigen-specific T cells 
ex vivo by flow cytometry. In this case, the MHC complex contained the TRP-2 derived 
peptide180-188 (SVYDFFVWL). 
Cells were prepared as described in 3.3.2. After Fc-blocking, cells were incubated with 10 µL 
PE-conjugated MHC dextramer for 10 min at 4 °C. Anti-mouse CD8-APC Cy7 and anti-mouse 
CCR5-APC were added and incubated another 20 min at 4 °C. Cells were washed four times 
with 200 µL FACS buffer and then measured with FACSCanto II.  
3.3.9 Analysis of MDSC migration capacity 
The transwell assay is a commonly used method to analyze the migratory capacity of cells due 
to chemotaxis. The transwell system consists of inserts with a permeable membrane of 0.3 µm 
micro pores. This membrane separates the well in an upper and lower chamber. Myeloid cells 
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from the BM of WT mice were isolated with the MDSC isolation kit (Miltenyi). In the upper 
chamber, 5x105 MDSC were seeded in medium supplemented with 40 ng/mL GM-CSF and 
40 ng/mL IL-6. The lower chambers were loaded with 10 ng/mL CCL3, 15 ng/mL CCL4 or 
40 ng/mL CCL5 as described (Sapir et al., 2010). The mCCR5-Ig fusion protein was added to 
a final concentration of 20 ng/mL. Cells migrated for 3 h at 37 °C, 5 % CO2. After incubation, 
the content of the lower chamber was collected and cells were counted three times with the 
Neubauer counting chamber.  
3.3.10 Therapy of ret transgenic mice with the mCCR5-Ig fusion protein 
mCCR5-Ig was constructed as previously described (Sapir et al., 2010) and provided by InVivo 
BioTech Services (Berlin). Ret transgenic tumor bearing mice were injected intraperitoneally 
(i.p.) with 10 mg/kg mCCR5-Ig in 200 µL PBS twice per week for three weeks. The control 
group of mice with tumors of similar size received the corresponding amount of anti-mouse 
immunoglobulin G (IgG) (Sigma-Aldrich). Both groups were monitored for tumor progression. 
3.3.11 Characteristics of melanoma patients at different stages 
Peripheral blood and metastases were obtained from 66 melanoma patients of stage I-IV 
(AJCC 2009) who were seen at the Skin Cancer Center (University Medical Center Mannheim, 
Germany) from January 2013 to August 2015 (ethics approval: 2010-318N-MA). Exclusion 
criteria were cardiac disease, autoimmune disease, diabetes mellitus, and immunotherapies 
within 6 months before the patient’s visit. Peripheral blood from 14 age- and gender-matched 
healthy donors (HD) without indications of immune-related diseases were obtained at the 
Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg 
University, German Red Cross Blood Service Baden Württemberg-Hessen (Mannheim, 
Germany) after informed consent and used as controls. Characteristics of patients and HD are 
listed in Table 15 
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Table 1: Characteristics of melanoma patients and HD 
Baseline characteristic  Melanoma patients Healthy donors 
Subjects  (n) 66 14 
Melanoma stage, n (%)   
I 16 (24.2%)  
II 20 (30.3%)  
III 19 (28.8%)  
IV 11 (16.6%)  
Sex, n (%)   
  Female 19 (28.8%) 6 (42.9%) 
  Male 47 (71.2%)  8 (57.1%) 
Age (years)a (range) 62.37 (33-90) 59,82 (51-69) 
a Age at the blood draw 
 
3.3.12 PBMC isolation from human peripheral blood samples 
Peripheral blood from heparinized venous blood and skin metastasis was obtained from 
untreated melanoma patients of different stages (stage I-IV) in the Department of Dermatology 
(University Medical Center Mannheim). Peripheral blood mononuclear cells (PBMC) were 
isolated from the peripheral blood by density gradient centrifugation. Two Leucosep tubes per 
patient were filled with 15 mL Biocoll and spun down at 1400 rpm for 10 sec. Blood was diluted 
with 15 mL RPMI before distributing it equally to the prepared Leucosep tubes and centrifuged 
at 2000 rpm for 20 min (without break). PBMC layers of both Leucosep tubes were carefully 
removed with a pasteur pipet and washed with RPMI in a final volume of 50 mL at 1400 rpm 
for 7 min. The pellet was resuspended in an appropriate amount of X-VIVO 20 to count the 
cells and then washed again. Isolated PBMC were directly stained and measured by flow 
cytometry or stored in liquid nitrogen until the time of experimentation. 1x107 cells were 
resuspended in 500 µL freezing medium 1 (see 3.1.8). Afterwards, 500 µL freezing medium 2 
(see 3.1.8) was added to the cell suspension and frozen in “Mr. Frosty” overnight. The other 
day, cells were transferred from -80 °C to liquid nitrogen for long term storage.  
Frozen cryotubes were shortly submerged in a 37 °C water bath till the cell suspension was 
almost thawed. Cells were transferred in 15 mL tubes and washed with 10 mL RPMI at 
1400 rpm for 10 min before staining for FACS analysis. 
Serum was collected from venous blood samples after centrifugation at 1400 rpm for 10 min 
and frozen at -20 °C until bio-plex assay was performed.  
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3.3.13 Preparation of tumor samples from melanoma patients 
Fresh melanoma skin metastasis was smashed mechanically with a plunger through a 40 µm 
cell strainer to get a single cell suspension. Cells were washed with PBS and lysis of the 
erythrocytes was performed as described for mouse tumors. Single cell suspension was 
stained on the same day and measured by flow cytometry. 
3.3.14 Statistical analysis 
Statistical analyses were performed using GraphPad Prism software. Results were assessed 
with a one-way ANOVA test or an unpaired two-tailed Student’s t test. Throughout the analysis, 
p < 0.05 was considered as statistically significant.  
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4 Results 
4.1 The role of CCR5-CCR5 ligand interaction in melanoma-bearing mice 
It has been previously demonstrated that MDSC are active and accumulate during tumor 
progression in ret transgenic mice and in melanoma patients (Meyer et al., 2011; Jiang et al., 
2015). To address the question whether CCR5 plays a role in the recruitment and activity of 
immunosuppressive cells, we analyzed the CCR5-CCR5 ligand interaction in ret transgenic 
melanoma bearing mice and in melanoma patients.  
4.1.1 CCR5 expression on MDSC in melanoma-bearing mice 
To identify mouse CCR5+ MDSC the following monoclonal antibodies (mAb) were used: 
anti-CD11b, anti-Gr-1, anti-CCR5, anti-Ly6C and anti-CD45.2 (for skin tumors). Upon gating 
for singlets, live cells and CD11b/Gr1 double positive cells were gated (Fig. 2). Whole MDSC 
populations were gated for CCR5+ and CCR5- MDSC. Mouse MDSC were further 
characterized as monocytic (Ly6Chigh) and granulocytic (Ly6Clow/neg) MDSC and then analyzed 
for their immunosuppressive phenotype by NO and ROS production, as well as PD-L1 and 
ARG-1 expression, of each CCR5 MDSC subset.  
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Figure 2: Gating strategy of CCR5 expressing CD11b+Gr1+ cells (MDSC) in the BM of tumor 
bearing mice. Representative dot plots of the BM are shown.  
 
The expression of CCR5 on mouse MDSC was assessed in the BM, peripheral blood, spleen, 
metastatic LN and skin tumor samples (Fig. 3). The frequency of CCR5 expressing MDSC in 
melanoma lesions was elevated as compared to that in the periphery (the BM and peripheral 
blood) (Fig. 3A). The CCR5 expression intensity on MDSC was higher in skin tumors as 
compared to the peripheral blood (Fig. 3B). To study the relation between the frequency of 
invading CCR5 expressing MDSC at the tumor site and metastatic LN during melanoma 
progression, we performed a linear regression analysis. It was shown that the accumulation of 
CCR5+ MDSC in skin tumors and metastatic LN correlated with increased tumor weight, which 
was used as an indicator of tumor progression (Fig. 3C, D). Furthermore, the level of CCR5 
expression on MDSC increased in melanoma lesions with tumor weight (Fig. 3E,F). These 
findings suggest that CCR5 is an important molecule for the migration of MDSC to melanoma 
lesions. 
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Figure 3: CCR5 expression on MDSC of ret transgenic tumor bearing mice. A. CCR5 expressing 
MDSC in BM, peripheral blood, spleen, metastatic LN and skin tumors were measured by flow 
cytometry. Results are shown as the percentage of CCR5+ MDSC within total MDSC (mean and SEM). 
B. The intensity of CCR5 expression on MDSC is presented as the mean fluorescence intensity (MFI) ± 
SEM. The weight of each tumor sample was plotted against the percentage of tumor-infiltrating CCR5 
expressing MDSC within total MDSC in skin tumors (C, n=24) and metastatic LN (D, n=32). The intensity 
of CCR5 expression on MDSC in skin tumors (E, n=22) and metastatic LN (F, n=28) was plotted against 
the tumor weight. The correlation was calculated using a linear regression analysis. 500,000 live cells 
in BM and peripheral blood, 800,000 live cells in spleen and metastatic LN and 200,000 CD45+ live cells 
in skin tumor were analyzed. *p < 0.05, ***p < 0.001.  
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4.1.2 CCR5 expression pattern on MDSC subsets in tumor bearing mice 
We next aimed to investigate the expression of CCR5 on MDSC subsets. Fig. 4 shows the 
frequency of CCR5+ Gr-MDSC and Mo-MDSC in the BM, peripheral blood, spleen, metastatic 
LN and skin tumors during melanoma development. The frequency of CCR5 expressing 
Gr-MDSC was raised in skin tumors as compared to the BM, peripheral blood and spleen (Fig. 
4A). The frequency of CCR5 expressing Mo-MDSC was also elevated in skin tumors as 
compared to the BM, peripheral blood and spleen (Fig. 4B). This CCR5 expression pattern is 
similar to the situation with the total population of MDSC.  
Furthermore, we found significantly higher CCR5 expression on Gr-MDSC in metastatic LN 
and spleen than on the monocytic subpopulation in these organs (Fig. 4C). In accordance with 
our data on the frequency of CCR5+ Gr-MDSC, the intensity of CCR5 expression in skin tumors 
was higher than in the BM, peripheral blood and spleen (Fig. 4D). For Mo-MDSC, the level of 
CCR5 expression in skin tumors and metastatic LN was enhanced as compared to the 
peripheral blood (Fig. 4E). Analyzing different MDSC subsets, the intensity of CCR5 
expression on Gr-MDSC in skin tumors was found to be increased as compared to the 
monocytic subset (Fig. 4F). 
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Figure 4: Expression of CCR5 on Gr-MDSC and Mo-MDSC in tumor bearing mice. CCR5 
expression on Gr- (CD11b+Ly6G+Ly6C-) and Mo- (CD11b+Ly6G-Ly6C+) MDSC in BM, peripheral blood, 
spleen, metastatic LN and skin tumor was measured by flow cytometry. The frequency of CCR5+ 
Gr-MDSC (A, n=28) and CCR5+ Mo-MDSC (B, n=27) within total CCR5+ MDSC was analyzed in tumor 
bearing mice (mean and SEM). C. A direct comparison between the frequency of CCR5+ Gr-MDSC and 
CCR5+ Mo-MDSC among total CCR5+ MDSC (n=27-28). D. Expression level of CCR5 on Gr-MDSC 
(n=28) and E. Mo-MDSC (n=27) is presented as MFI ± SEM. F. The intensity of CCR5 expression on 
Gr-MDSC was compared to Mo-MDSC and is shown as MFI ± SEM (n=28). *p < 0.05, **p < 0.01, 
***p < 0.001. 
 
4.1.3 Increased production of chronic inflammatory mediators in melanoma lesions 
To evaluate factors involved in the activation and recruitment of MDSC, serum, metastatic LN 
and skin tumors were collected. Melanoma lesions were lysed and protein concentration was 
determined in serum and lysates using a bio-plex assay (Fig. 5). We found that metastatic LN 
displayed the highest level of CCL3, CCL4, CCL5, CCL2, IP-10, IL-6, VEGF, and TGF-β. 
Importantly, their concentrations in skin tumors were also significantly higher than in serum. 
These results suggest that the secretion of chronic inflammatory factors support the activation 
of CCR5+ MDSC and also the migration of these cells to the melanoma microenvironment. 
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Figure 5: Production of chronic inflammatory mediators in melanoma bearing mice. Concentration 
of CCL3, CCL4, CCL5 (A-C, n=25), CCL2 (D, n=16), IP-10, IL-6, VEGF, TGF-β (E-H, n=17) was 
measured in serum and lysates of metastatic LN and skin tumors using bio-plex assay. Results are 
expressed as pg/mg protein (mean ± SEM). **p < 0.01, ***p < 0.001. 
IP-10
se
ru
m
m
et
as
ta
tic
 L
N
sk
in
 tu
m
or
0
2
4
6
8
10
50
100
150
***
***
IP
-1
0
 [
p
g
/m
g
]
IL-6
se
ru
m
m
et
as
ta
tic
 L
N
sk
in
 tu
m
or
0.0
0.2
0.4
0.6
0.8
1.0
10
20
30
***
***
IL
-6
 [
p
g
/m
g
]
VEGF
se
ru
m
m
et
as
ta
tic
 L
N
sk
in
 tu
m
or
0.0
0.2
0.4
0.6
0.8
1.0
50
100
150
200
250
**
**
V
E
G
F
 [
p
g
/m
g
]
TGF-ß
se
ru
m
m
et
as
ta
tic
 L
N
sk
in
 tu
m
or
0
200
400
600
800 ***
***
T
G
F
- β
 [
p
g
/m
g
]
CCL3
se
ru
m
m
et
as
ta
tic
 L
N
sk
in
 tu
m
or
0.0
0.1
0.2
0.3
0.4
0.5
10
20
30
40
50
60
***
***
C
C
L
3
 p
g
/m
g
 p
ro
te
in
CCL4
se
ru
m
m
et
as
ta
tic
 L
N
sk
in
 tu
m
or
M
0.0
0.2
0.4
0.6
0.8
1.0
10
20
30
40
50
60 ***
***
C
C
L
4
 p
g
/m
g
 p
ro
te
in
CCL5
se
ru
m
m
et
as
ta
tic
 L
N
sk
in
 tu
m
or
0.0
0.5
1.0
4
6
8
10
300
350
400
***
***
C
C
L
5
 p
g
/m
g
 p
ro
te
in
A B
C D
E F
G
Results  38 
__________________________________________________________________________ 
 
 
4.1.4 Production of chronic inflammatory mediators in melanoma lesions during 
tumor development 
Chronic inflammatory factors produced in the process of melanoma development play an 
important role in tumor growth but also in the recruitment of immune cells to the site of the 
tumor. To get insights into their distribution and concentration during tumor development, we 
measured their production in tumors with different weights (Fig. 6). The level of CCL3, VEGF 
and TGF-β was found to be significantly increased, whereas CCL5 production was elevated 
only slightly in skin tumors. In contrast, the production of CCL3 was decreased during tumor 
progression in metastatic LN.  
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Figure 6: Chronic inflammatory mediators during tumor progression. The level of CCL3 (A, n=22), 
CCL5 (B, n=18), VEGF (C, n=15), TGF-β (D, n=14) production in skin tumors and CCL3 (E, n=14) 
production in metastatic LN was plotted against the tumor weight. The correlation was evaluated by a 
linear regression analysis. **p < 0.001, ***p < 0.001.  
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4.1.5 Immunosuppressive activity of CCR5+ MDSC in tumor bearing mice 
4.1.5.1 Immunosuppressive phenotype of CCR5+ MDSC  
Since NO and ROS production, as well as ARG-1 expression, are considered as key factors 
of the immunosuppressive phenotype of MDSC (Lu and Gabrilovich, 2012), we measured 
these molecules in CCR5+ MDSC from the BM, peripheral blood, spleen, and melanoma 
lesions. We found that CCR5+ MDSC from skin tumors and the peripheral blood produced 
significantly more NO than their CCR5- counterparts, indicating an enhanced 
immunosuppressive capacity of the CCR5+ MDSC subset (Fig. 7A). Interestingly, the level of 
NO production in CCR5+ MDSC from melanoma lesions was increased as compared to these 
cells in the peripheral blood.  
Next, we analyzed ROS production and observed that in the BM, spleen, metastatic LN and 
skin tumors, CCR5+ MDSC produced significantly more ROS as compared to the CCR5- 
MDSC (Fig. 7B). In addition, ROS production by CCR5+ MDSC in metastatic LN was higher 
than in the peripheral blood. The frequency of ROS producing CCR5+ MDSC was elevated in 
metastatic LN and skin tumor as compared to peripheral blood (Fig. 7C).  
Furthermore, the level of ARG-1 expression on CCR5+ MDSC in peripheral blood, spleen, 
metastatic LN and skin tumor was upregulated as compared to the CCR5- counterpart 
(Fig. 7D). We also studied PD-L1 expression on CCR5+ MDSC. Interestingly, the frequency of 
PD-L1 expressing CCR5+ MDSC in all analyzed organs was significantly increased as 
compared to the CCR5- MDSC subset (Fig. 7E). The level of PD-L1 expression on CCR5+ 
MDSC was higher in melanoma lesions as compared to the BM and peripheral blood (Fig. 7F). 
To conclude, CCR5+ MDSC demonstrated an enhanced immunosuppressive phenotype 
reflected by increased NO and ROS production, as well as ARG-1 and PD-L1 expression, 
when compared to their CCR5- counterpart. 
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Figure 7: Immunosuppressive phenotype of CCR5+ MDSC in ret transgenic mice. BM, blood, 
spleen, metastatic LN and skin tumors were isolated from tumor bearing mice and stained for flow 
cytometry. Direct comparison between CCR5+ MDSC and CCR5- MDSC in the production of NO (A.) 
and ROS (B.) is shown and expressed as MFI ± SEM. C. The frequency of ROS producing cells by 
CCR5+ MDSC in different organs is presented as the number of ROS producing cells among CCR5+ 
MDSC (mean ± SEM). D. The level of ARG-1 expression on CCR5+ MDSC and CCR5- MDSC was 
NO production
B
M
bl
oo
d
sp
le
en
m
et
as
ta
tic
 L
N
sk
in
 tu
m
or
0
1000
2000
3000
CCR5-NO+
CCR5+NO+
*
***
***
***
B
M
bl
oo
d
sp
le
en
m
et
as
ta
tic
 L
N
sk
in
 tu
m
or
R
O
S
 p
ro
d
u
c
ti
o
n
, 
M
F
I
Arg-1 expression
B
M
bl
oo
d
sp
le
en
m
et
as
ta
tic
 L
N
sk
in
 tu
m
or
0
2000
4000
6000
8000
CCR5+Arg-1+
CCR5-Arg-1+
***
**
*
*
B
M
bl
oo
d
sp
le
en
ly
m
ph
 n
od
es
sk
in
 tu
m
or
B
M
bl
oo
d
sp
le
en
m
et
as
ta
tic
 L
N
sk
in
 tu
m
or
B
M
bl
oo
d
sp
le
en
m
et
as
ta
tic
 L
N
sk
in
 tu
m
or
A B
C
D E
F
Results  42 
__________________________________________________________________________ 
 
 
assessed and is shown as MFI ± SEM. E. The frequency of PD-L1 expressing CCR5+ MDSC and CCR5- 
MDSC was analyzed and is presented as the percentage of CCR5 expressing MDSC among the 
respective cell subset (mean and SEM). F. Frequency of PD-L1 expressing CCR5+ MDSC in different 
organs are presented (BM, n=27; peripheral blood, n=25; spleen, n=27; metastatic LN, n=27; skin tumor, 
n=25). *p < 0.05, **p < 0.01, ***p < 0.001. 
 
4.1.5.2 Immunosuppressive phenotype of CCR5+ MDSC in melanoma lesions during 
tumor progression 
To determine the immunosuppressive phenotype of CCR5+ MDSC in course of melanoma 
progression, we analyzed NO and ROS production and the ARG-1 and PD-L1 expression in 
CCR5+ MDSC at different phases of melanoma progression (Fig. 8). It was found that the 
frequency of NO producing CCR5+ MDSC increased in skin tumors and metastatic LN (Fig. 8 
A,B) during tumor development. Furthermore, we found an increased frequency of ROS 
producing CCR5+ MDSC in skin tumors and metastatic LN (Fig. 8 C-F), as well as a higher 
intensity of ROS production in these organs during melanoma progression. Moreover, tumor-
infiltrating CCR5+ MDSC that express ARG-1 accumulated in melanoma lesions and the level 
of ARG-1 expression raised with tumor load (Fig. 8 G-I). Interestingly, the frequency of PD-L1 
expressing CCR5+ MDSC and also the intensity of PD-L1 expression of these cells were 
elevated with increasing tumor weight in skin tumors and metastatic LN (Fig. 8 J-M).  
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Figure 8: Functional phenotype of CCR5+ MDSC in melanoma lesions in course of tumor 
progression. NO and ROS production, as well as ARG-1 and PD-L1 expression of CCR5+ MDSC, was 
analyzed by flow cytometry and was plotted against the tumor load. Frequency of NO production in skin 
tumors (A, n=17) and intensity of NO production in metastatic LN (B, n=24) was measured. The 
frequency of ROS producing CCR5+ MDSC in melanoma lesions (skin tumor C. and metastatic LN E.) 
and the intensity of ROS production in skin tumors and metastatic LN is shown in D. and F. The 
expression of ARG-1 is presented as the percentage of CCR5+ MDSC (G). The ARG-1 expression 
intensity in CCR5+ MDSC in skin tumors (H) and metastatic LN (I) is presented as MFI. The frequency 
of PD-L1 expressing CCR5+ MDSC in skin tumors (J) and metastatic LN (K) and the level of PD-L1 
expression on CCR5+ MDSC is shown in melanoma lesions (L, M). The correlation was evaluated by a 
linear regression analysis. *p < 0.05, **p < 0.01, ***p < 0.001. 
 
4.1.6 Immunosuppressive effect of CCR5+ MDSC on CD8+ T cells 
In previous studies, MDSC from ret transgenic tumor bearing mice were shown to block the 
activation and proliferation of T cells (Meyer et al., 2011). Here, we performed a proliferation 
assay evaluating the ability of CCR5+ MDSC to inhibit T cell proliferation. For this experiment, 
CCR5+ and CCR5- MDSC subsets were isolated from the BM of tumor bearing mice by FACS. 
CD8+ T cells were isolated from the spleen of WT mice by magnetic cell sorting, labeled with 
CFSE and stimulated with anti-CD3/CD28 beads. CCR5+ MDSC or CCR5- MDSC were 
co-cultured with T cells for three days and T cell proliferation was measured via CFSE dilution 
by FACS analysis (Fig. 9A). We observed that both CCR5+ and CCR5- MDSC inhibited 
proliferation of stimulated T cells as compared to T cells cultured alone (Fig. 9B). Moreover, 
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we detected a dose-dependent effect of MDSC on T cell proliferation. Comparing effects of 
BM-derived MDSC subsets, we found that CCR5+ MDSC exerted a tendency for stronger 
inhibition of T cell proliferation than their CCR5- counterparts (Fig. 9B).  
Taken together, CCR5+ MDSC showed significantly higher NO and ROS production, as well 
as an elevated ARG-1 and PD-L1 expression as compared to CCR5- MDSC derived from the 
same organ. Moreover, they displayed a slightly stronger capacity to suppress T cell 
proliferation than CCR5- cells. 
 
 
 
 
 
 
 
 
 
Figure 9: CCR5+ MDSC from ret transgenic mice inhibit T cell proliferation. CCR5+ MDSC and 
CCR5- MDSC from BM of tumor bearing mice were sorted by FACSAria and co-cultured at different 
ratios with CFSE-labeled CD8+ T cells isolated from naïve C57BL/6 splenocytes and stimulated with 
anti-CD3/CD28 beads. Proliferation was assessed by CFSE dilution on day 3 by flow cytometry. A. A 
representative histogram assessing T cell proliferation is shown. B. The frequency of proliferating T cells 
cultured with MDSC at different ratios is presented. Data represents the mean of three experiments 
(mean ± SEM). 
 
4.1.7 Chemokine-mediated migration capacity of MDSC  
Next, we investigated the impact of chemokines on the migration of MDSC. Therefore, we 
performed a chemotaxis assay in a transwell system (Fig. 10). In this assay, we analyzed the 
CCR5 ligand-mediated migration of IMC isolated from the BM of WT mice and the 
neutralization capacity of the fusion protein mCCR5-Ig (Sapir et al., 2010). This fusion protein 
encodes 30 amino acids of the second extracellular domain of CCR5 and thus binds and 
neutralizes the biological function of all three CCR5 ligands. As a control for the mCCR5-Ig, 
we used an anti-mouse IgG antibody. We found that the migration of IMC was significantly 
induced by each of the CCR5 ligands CCL3, CCL4 and CCL5 as compared to medium without 
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any supplements. Analyzing the IMC migration with all three CCR5 ligands, we found no 
stimulation of migration capacity as compared to the single ligand-mediated migration. 
Importantly, the mCCR5-Ig fusion protein significantly abrogated the ligand-induced migration 
of IMC. Therefore, we demonstrated that the CCR5-CCR5 ligand axis is crucial for the 
migration of IMC ex vitro.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: CCR5 ligand-induced migration capacity of CD11b+Gr-1+ cells. IMC were isolated from 
the BM of healthy C57BL/6 mice using the MDSC Isolation kit. Chemotaxis assay was performed in a 
transwell system. 2x106 cells were incubated for 3 h at 37°C. The lower chamber contained single 
chemokines (15 ng/mL CCL3, 10 ng/mL CCL4 or 50 ng/mL CCL5) or a combination (CCL3, 
CCL4,CCL5). mCCR5-Ig (20 ng/mL) or anti-mouse IgG as a control was added. Data of two experiments 
are presented as the percentage of migrated CD11b+Gr-1+ cells among total cells (mean and SEM). 
*p < 0.05.  
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4.1.8 Role of CCR5 on various T cell subsets in melanoma-bearing mice 
4.1.8.1 CCR5 expression on various T cell subsets infiltrating melanoma lesions 
Next, we studied the expression of CCR5 on T cells from ret transgenic tumor bearing mice 
since it was described its expression on various T cell subsets (Fukada et al., 2002; Ward et 
al., 2015).  
We collected the peripheral blood, spleen, metastatic LN and skin tumors of ret transgenic 
tumor bearing mice, prepared a single cell suspension and stained it with different T cell 
markers. Fig. 11 shows a representative gating strategy of CCR5 expressing CD4+ Treg, naïve 
CD4+ T cells, activated CD4+ T cells and CD8+ T cells. We first gated singlets and live cells, 
followed by the identification of CD3+ T cells. Then T cells were divided on CD4+ and CD8+ 
T cells. CD4+CD25+FoxP3+ T cells were identified as Treg. CD25-FoxP3- cells represented 
CD4+ naïve T cells and CD25+FoxP3- were classified as CD4+ activated T cells. All CD4+ and 
CD8+ T cell subsets were then gated for CCR5+ and CCR5- expression followed by the analysis 
of activation markers (CD69, PD-1, TCR ζ-chain) to evaluate their functional status.  
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Figure 11: Gating strategy of CCR5 expressing T cell subsets in splenocytes of ret transgenic 
mice.  Representative dot plots of the spleen are shown.  
 
We analyzed the CCR5 expression on various T cell subsets of ret transgenic tumor bearing 
mice. In melanoma lesions, the highest frequency of CCR5 expressing cells was detected 
among Treg (Fig. 12A, B). Interestingly, the frequency of CCR5+ cells among naïve CD4+, 
activated CD4+ and CD8+ T cells was significantly lower than on CD4+ Treg subset. Therefore, 
immunosuppressive Treg infiltrating melanoma lesions are characterized by enhanced CCR5 
expression as compared to conventional CD4+ and CD8+ T cells.  
Studying the frequency of CCR5+CD4+ Treg in different organs, we observed an increased 
frequency of CCR5+ Treg in melanoma lesions as compared to the peripheral blood (Fig. 12C). 
Furthermore, CCR5 expression intensity was higher in metastatic LN than in the peripheral 
blood (Fig. 12D).  
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Figure 12: CCR5 expression on various T cell subsets of ret transgenic mice. Metastatic LN and 
skin tumors were isolated from tumor bearing mice and single cell suspension was prepared. Cells were 
analyzed by flow cytometry. CCR5 expression on naïve and activated CD4+ T cells, CD4+ Treg and 
CD8+ T cells were analyzed in skin tumors (A, n=12-20) and metastatic LN (B, n=12-20). Data is 
presented as the frequency of the respective T cells subset (mean and SEM). The frequency of CCR5 
expressing Treg (C, n=15-19) and the intensity of CCR5 expression (D, n=15-20) were assessed in 
peripheral blood, spleen, metastatic LN and skin tumors of the same tumor bearing ret transgenic mouse 
(mean and SEM). *p < 0.05, **p < 0.01, ***p < 0.001. 
 
4.1.8.2 Distribution of CCR5 expressing Treg subsets in melanoma lesions 
Similar to MDSC, Treg are known to play an immunosuppressive role in the tumor 
microenvironment as they inhibit T cell proliferation. We examined tumor infiltration by CCR5+ 
Treg during melanoma development and further measured their frequency among Treg 
infiltrating tumors of different weights (as an indicator of tumor progression) (Fig. 13). We found 
that CCR5+ Treg infiltration significantly increased in skin tumors and metastatic LN during the 
course of melanoma progression (Fig. 13A, B). Analyzing the activation of CCR5+ Treg, we 
found an augmented frequency of CD69 expressing CCR5+ Treg in peripheral blood, spleen, 
and melanoma lesions as compared to their CCR5- Treg counterpart (Fig. 13C). Moreover, the 
intensity of CD69 expression on CCR5+ Treg in peripheral blood, and melanoma lesions was 
shown to be higher than on CCR5- Treg (Fig. 13D). A statistically significant accumulation of 
CD69+CCR5+ Treg was displayed in skin tumors as compared to the peripheral blood, spleen, 
and metastatic LN (Fig. 13E).  
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Figure 13: CCR5+ Treg in tumor bearing mice. Cells from the peripheral blood, spleen and melanoma 
lesions were measured by flow cytometry. The frequency of CCR5 expressing Treg in skin tumors (A, 
n=19) and metastatic LN (B, n=17) were plotted against the tumor weight. The activity of CCR5+ Treg 
was analyzed by CD69 expression. The frequency of CD69 expressing CCR5+ and CCR5- Treg in 
peripheral blood, spleen, metastatic LN and skin tumor was analyzed (mean and SEM) (C, n=17). The 
intensity of CD69 expression on CCR5+ and CCR5- Treg in the periphery and melanoma lesions is 
shown as MFI (D, n=17). The frequency of CD69 expression on CCR5+ Treg in tumor bearing mice is 
presented in E (mean and SEM, n=17). *p < 0.05, **p < 0.01, ***p < 0.001. 
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4.1.8.3 TRP-2 specific CCR5+CD8+ T cells in the ret transgenic mouse melanoma model 
To elucidate the tumor-specific immunity in the ret transgenic mouse melanoma model, we 
used MHC dextramers specific for the tumor associated antigen TRP-2. TRP-2 is expressed 
by melanoma cells and recognized by cytotoxic CD8+ T cells (Wang et al., 1996). We found 
that the frequency of TRP-2 specific CCR5+CD8+ T cells is significantly increased in the 
periphery, as well as in metastatic LN and skin tumors as compared to their CCR5- 
counterparts (Fig. 14A). Furthermore, we detected that the frequency of melanoma specific 
CCR5 expressing CD8+ T cells was elevated in melanoma lesions (Fig. 14B). However, these 
tumor-specific CCR5+CD8+ T cells were reduced in course of tumor progression in skin tumors 
and metastatic LN (Fig. 14C, D). These data indicate that the greatest part of TRP2-specific 
CD8+ T cells was CCR5+, which decreased during melanoma development. This result was in 
contrast to the CCR5+ MDSC that increased with tumor progression. 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: TRP-2 specificity of CCR5 expressing, CD8+ T cells in melanoma bearing mice. Direct 
comparison between CCR5+ and CCR5- melanoma specific, CD8+ T cells in peripheral blood, spleen, 
metastatic LN and skin tumor was performed by flow cytometry (A, n=11). Results are presented as the 
frequency of TRP2-specific CCR5+CD8+ T cells (mean ± SEM). The frequency of TRP-2 specific 
CCR5+CD8+ T cells in blood and melanoma lesions is presented (mean and SEM) (B, n=11). A 
correlation between the TRP-2 specific CCR5+CD8+ T cells and the tumor weight in skin tumors (C, 
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n=11) and metastatic LN (D, n=10) was evaluated by a linear regression analysis. *p < 0.05, **p < 0.01, 
***p < 0.001.  
 
4.2 Treatment of ret transgenic tumor bearing mice with mCCR5-Ig 
4.2.1 Effect of soluble CCR5-Ig on survival of ret transgenic mice 
Tumor bearing ret transgenic mice were injected i.p. with mCCR5-Ig twice per week for 
3 weeks. The control group was treated with anti-mouse IgG. We found that treated mice 
displayed a significantly increased survival as compared to the control group (Fig. 15). Thus, 
in the therapy group, 3 out of 7 mice were living 53 days after the treatment onset, whereas all 
mice in the control group died after 49 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Survival of tumor bearing mice after mCCR5-Ig treatment. Mice were injected i.p. with 
mCCR5-Ig (10 mg/kg in 200 µl) twice per week for 3 weeks. Mice in the control group received the same 
concentration of anti-mouse IgG. Survival of mice (n=7-8 mice) is shown as a Kaplan-Meier curve.  
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4.2.2 Analysis of immune cells in mCCR5-Ig treated tumor bearing mice 
Next, we aimed to analyze the effect of mCCR5-Ig therapy on different immune cell populations 
in the BM, peripheral blood, metastatic LN and skin tumors. Mice were treated for three weeks 
followed by the study of MDSC, Treg, conventional CD4+ and CD8+ T cells one day after the 
last injection.  
As shown in Fig. 16A, the frequency of MDSC decreased in skin tumors of ret transgenic mice 
after mCCR5-Ig therapy as compared to the mice from control group. Moreover, we 
demonstrated that NO production by MDSC was significantly lower in skin tumors and the 
peripheral blood of mCCR5-Ig treated mice as compared to the control mice (Fig. 16B). 
Importantly, the frequency of CCR5+ MDSC was significantly reduced in skin tumors as 
compared to the control mice (Fig. 16C). Furthermore, the frequency of these cells was 
decreased during tumor development (Fig. 16D) indicating a blocking effect of the fusion 
protein mCCR5-Ig. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B
M
bl
oo
d
m
et
as
ta
tic
 L
N
sk
in
 tu
m
or
MDSC
B
M
bl
oo
d
m
et
as
ta
tic
 L
N
sk
in
 tu
m
or
0
1000
2000
3000
control Ig
CCR5-Ig
*
*
A B
C D
B
M
bl
oo
d
m
et
as
ta
tic
 L
N
sk
in
 tu
m
or
%
 o
f 
to
ta
l 
 M
D
S
C
CCR5+ MDSC in skin tumor
0 500 1000 1500
0
10
20
30
40
50
mCCR5-Ig
tumor weight, mg
P value 0.0055
R square 0.8138
Results  55 
__________________________________________________________________________ 
 
 
Figure 16: mCCR5-Ig reduced the frequency of tumor-infiltrating MDSC in ret transgenic mice. 
MDSC in BM, peripheral blood, metastatic LN and skin tumors in mCCR5-Ig treated (n=7) and control 
mice (n=8) were measured by flow cytometry. A. Frequency of MDSC in treated and control mice was 
assessed and results are presented as the percentage of total MDSC within alive cells (mean ± SEM). 
B. NO production of MDSC in the treated and untreated groups was determined and are presented as 
the MFI ± SEM. C. The frequency of CCR5+ MDSC in mCCR5-Ig treated mice and control mice is 
demonstrated and presented as percentage of CCR5+ MDSC within total MDSC (mean and SEM). D. 
The weight of each tumor sample was plotted against the percentage of tumor-infiltrating CCR5 
expressing MDSC within total MDSC in skin tumors (n=7). The correlation was calculated using linear 
regression analysis. 500,000 live cells in BM and peripheral blood, 800,000 live cells in metastatic LN 
and 200,000 CD45+ live cells in tumors were analyzed. p* < 0.05, p*** < 0,001. 
 
Analyzing different T cell populations, we found a decreased frequency of total Treg in skin 
tumors from treated mice as compared to the control group (Fig. 17A-B). In addition, the 
activation of Treg measured by CD69 expression was reduced in metastatic LN of treated mice 
as compared to the control (Fig. 17C). Importantly, the frequency of CCR5 expressing Treg 
was reduced in skin tumors after treatment (Fig. 17D). Moreover, we observed that the 
frequency of CCR5+ Treg was diminished with tumor progression (Fig. 17E). 
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Figure 17: Reduced frequency of Treg in mCCR5-Ig treated ret transgenic mice. A. The frequency 
of Treg, CD4+ and CD8+ T cells in BM, peripheral blood, metastatic LN and skin tumors was measured 
in treated (n=7) and control (n=8) mice groups by flow cytometry. Results are shown as the percentage 
of the respective T cell subset (mean and SEM). B. The frequency of Treg in various organs was 
assessed and is presented as the percentage of Treg within CD4+ T cells (mean and SEM). C. CD69 
expression on Treg was measured and is shown as the percentage of CD69+ Treg within Treg (mean 
and SEM). D. The frequency of CCR5 expressing Treg in various organs was analyzed and is presented 
as the percentage of CCR5+ Treg within total Treg (mean and SEM). E. The weight of each tumor sample 
was plotted against the percentage of tumor-infiltrating CCR5 expressing Treg within total CD4+ T cells 
in the skin tumors (n=7). The correlation was calculated using linear regression analysis. 500,000 live 
cells in BM and peripheral blood, 800,000 live cells in metastatic LN and 200,000 CD45+ live cells in 
tumors were analyzed. *p < 0.05, ***p < 0.001. 
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The data demonstrates that mCCR5-Ig can block the migration of immunosuppressive cells 
such as MDSC and Treg to the tumor microenvironment, indicating that the CCR5-CCR5 
ligand axis plays a major role in the recruitment of MDSC and Treg to the tumor site. Moreover, 
this was associated with the accumulation of non-regulatory CD4+ and CD8+ T cells in the 
tumor microenvironment. 
 
4.3 CCR5 expression on MDSC in melanoma patients 
4.3.1 Elevated CCR5 expression on Mo-MDSC and Gr-MDSC in melanoma patients 
during tumor progression 
Next, we studied the role of CCR5 expression in human MDSC. PBMC from the peripheral 
blood, as well as single cell suspension of metastasis from melanoma patients, were isolated 
and stained for the following markers: anti-human CD45.2, anti-human HLA-DR, anti-human 
CD11b, anti-human CD14, anti-human CD15, anti-human CCR5, anti-human PD-L1 and 
anti-human ARG-1. In addition, we detected NO and ROS. Unstained cells, as well as FMO, 
were used as negative controls. Human CCR5+ MDSC were identified by gating on singlets 
(Fig. 18). Human MDSC were gated for HLA-DRlow/neg and CD11b+ cells. Monocytic and 
granulocytic MDSC were identified by the expression of CD14 or CD15 respectively. Analysis 
of the immunosuppressive phenotype was performed by measuring NO and ROS production, 
as well as PD-L1 and ARG-1 expression on the different CCR5 cell subsets. 
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Figure 18: Gating strategy for CCR5+ MDSC from melanoma patients. MDSC from the peripheral 
blood of human melanoma patients. PBMC were isolated by density gradient centrifugation and frozen 
in liquid nitrogen. Cells were then thawed and stained for FACS analysis 
 
CCR5+ MDSC were studied in skin metastasis and peripheral blood of melanoma patients with 
different stages by flow cytometry. Interestingly, we found no expression of CCR5 on CD45.2- 
tumor cells (data not shown). Melanoma patients showed a significantly higher frequency of 
Mo-MDSC as compared to their counterparts in HD (Fig. 19A). For the granulocytic subset, we 
could not detect any differences in the frequency as compared to HD or in melanoma patients 
at different stages (Fig. 19B). Next, we investigated the CCR5 expression on Mo-MDSC and 
Gr-MDSC in patients with melanoma in different stages. The frequency of CCR5+ Mo-MDSC, 
as well as CCR5+ Gr-MDSC, was significantly increased in melanoma patients as compared 
to HD (Fig. 19C, D). Moreover, we could show a significant increase in the intensity of CCR5 
expression on Mo-MDSC in patients of different stages as compared to IMC in HD (Fig. 19E,F). 
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Figure 19: Analysis of CCR5+ MDSC of melanoma patients during course of tumor progression.
PBMC from the peripheral blood of melanoma patients and HD were assessed by flow cytometry. The 
frequency of Mo-MDSC (A) and Gr-MDSC (B) in melanoma patients and HD is presented as the 
percentage of these cells within live PBMC. The frequency of CCR5+ Mo-MDSC (C) and CCR5+
Gr-MDSC (D) is shown as the percentage of the respective MDSC subset. CCR5 expression level of 
Mo-MDSC (E) and Gr-MDSC (F) is shown as the mean fluorescence intensity (MFI). *p < 0.05, 
**p < 0.01, ***p < 0.001. 
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4.3.2 Immunosuppressive phenotype of CCR5+ Mo-MDSC and CCR5+ Gr-MDSC in 
melanoma patients 
To evaluate the immunosuppressive phenotype of circulating CCR5+ Mo-MDSC and CCR5+ 
Gr-MDSC in melanoma patients at different stages, we analyzed the NO and ROS production 
as well as the ARG-1 and PD-L1 expression (Fig. 20).  
The level of NO production by CCR5+ Mo-MDSC in stage III melanoma patients was 
significantly elevated as compared to stage I patients (Fig. 20A). The intensity of NO production 
by CCR5+ Gr-MDSC was higher in patients of stage II and III than in stage I patients (Fig. 20B). 
Furthermore, in patients with advanced melanoma (stage III and stage IV), CCR5+ Mo-MDSC 
showed higher NO production than their CCR5- Mo-MDSC counterpart (Fig. 20C). CCR5+ 
Gr-MDSC from patients stage III and stage IV also produced more NO as compared to their 
CCR5- counterpart (Fig. 20D).  
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Figure 20: NO production of CCR5+ MDSC in melanoma patients. PBMC were isolated from the 
peripheral blood from melanoma patients and HD and analyzed by flow cytometry. The NO production 
by CCR5+ Mo-MDSC (A) and CCR5+ Gr-MDSC (B) was plotted against melanoma patients at different 
stages and HD. Data is presented as the MFI of NO in CCR5+ MDSC subsets. C. and D. show the NO 
production in CCR5+ and CCR5- MDSC subsets in melanoma patients and HD (mean and SEM). 
*p < 0.05. 
 
The analysis of patients at various stages of melanoma revealed that CCR5+ Mo-MDSC from 
stage IV patients produced significantly more ROS than stage III and stage I patients and their 
myeloid counterparts in HD (Fig. 21A). The analysis of ROS producing CCR5+ Gr-MDSC 
showed that the ROS intensity was increased in melanoma patients with stage II as compared 
to stage I patients (Fig. 21B). The frequency of ROS producing CCR5+ Mo-MDSC in stage II 
and III melanoma was elevated as compared to their CCR5- counterparts (Fig. 21C). 
Furthermore, the level of ROS production in CCR5+ Gr-MDSC was higher in patients of stage 
II and III as compared to their CCR5- counterparts (Fig. 21D). 
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The frequency of ARG-1 expressing CCR5+ Mo-MDSC was found to be increased in the group 
containing all melanoma patients as compared to HD (Fig. 22A). In addition, the frequency of 
ARG-1 expressing CCR5+ Mo-MDSC was elevated in patients of stage III and II as compared 
to stage I melanoma patients. For the granulocytic subset, we detected that stage IV melanoma 
patients had an increased frequency of ARG-1 expressing CCR5+ cells as compared to those 
in stage I melanoma patients and their healthy counterparts (Fig. 22B). Also the frequency of 
ARG-1 expressing CCR5+ Gr-MDSC from melanoma patients of all groups was raised as 
compared to the MDSC counterpart in HD. Stage II, III, and IV melanoma patients showed a 
higher frequency of ARG-1 expressing CCR5+ Mo-MDSC than ARG-1 expressing 
CCR5- Mo-MDSC (Fig. 22C). When comparing circulating ARG-1 expressing Gr-MDSC in 
patients of different stages, we found a higher frequency of ARG-1 expressing CCR5+ 
Gr-MDSC than CCR5- Gr-MDSC in melanoma patients of stage II, III and IV (Fig. 22D). 
Furthermore, the level of ARG-1 expression measured as MFI was higher in CCR5+ Mo-MDSC 
from stage II, III, and IV patients as compared to their CCR5- counterpart (Fig. 22E). 
Figure 21: ROS production of CCR5+ MDSC in melanoma patients. PBMC were isolated from the 
peripheral blood from melanoma patients and HD and analyzed by flow cytometry. The ROS production 
of CCR5+ Mo-MDSC (A) and CCR5+ Gr-MDSC (B) was plotted against melanoma patients at different 
stages and HD. Data is presented as the MFI of ROS in CCR5+ MDSC subsets. C. and D. show the 
ROS production in CCR5+ and CCR5- MDSC subsets in melanoma patients and HD (mean and SEM). 
*p < 0.05. 
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Next, we analyzed the PD-L1 expression on CCR5+ MDSC subsets in melanoma patients. The 
frequency of CCR5+ Mo-MDSC (Fig. 23A) and CCR5+ Gr-MDSC (Fig. 23B) was increased in 
stage III melanoma patients as compared to stage I and II patients and to HD. However, we 
could not detect any significant differences in the PD-L1 expression between CCR5+ and 
CCR5- MDSC subsets (Fig. 23C, D). 
Figure 22: ARG-1 expression on CCR5+ MDSC in melanoma patients. PBMC were isolated from the 
peripheral blood from melanoma patients and HD and analyzed by flow cytometry. The frequency of 
ARG-1 expression on CCR5+ Mo-MDSC (A) and CCR5+ Gr-MDSC (B) was plotted against melanoma 
patients at different stages and HD. Data is presented as the percentage of ARG-1 expressing CCR5+
MDSC subsets. C. and D. show the ARG-1 expression in CCR5+ and CCR5- MDSC subsets in 
melanoma patients and HD (mean and SEM). The intensity of ARG-1 expression on CCR5+ and CCR5-
MDSC of melanoma patients and HD is presented as MFI (E). *p < 0.05, **p < 0.01, ***p < 0.001. 
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4.3.3 Accumulation of CCR5+ Mo-MDSC in skin tumors of melanoma patients 
To elucidate the role of CCR5 in the recruitment of MDSC and Treg to the tumor 
microenvironment in melanoma patients, we studied peripheral blood and tumor tissue 
samples from the same patient. We found a significantly increased frequency of CCR5+ 
Mo-MDSC in tumor tissue as compared to the peripheral blood (Fig. 24A). In contrast, the 
frequency of CCR5+ Gr-MDSC in the tumor tissue was only slightly increased (Fig. 24B).  
Figure 23: PD-L1 expression on CCR5+ MDSC in melanoma patients. PBMC were isolated from the 
peripheral blood from melanoma patients and HD and analyzed by flow cytometry. The frequency of 
PD-L1 expression on CCR5+ Mo-MDSC (A) and CCR5+ Gr-MDSC (B) was plotted against melanoma 
patients at different stages and HD. Data is presented as the percentage of PD-L1 expressing CCR5+
MDSC subsets. C. and D. show the PD-L1 expression in CCR5+ and CCR5- MDSC subsets in 
melanoma patients and HD (mean and SEM). **p < 0.01, ***p < 0.001. 
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Figure 24: CCR5 expression on immunosuppressive cells in melanoma patients. PBMC and skin 
metastasis cells from stage III and IV melanoma patients were analyzed by flow cytometry. The 
frequency of CCR5 expression on Mo-MDSC (A), Gr-MDSC (B) is shown. Data is presented as the 
percentage of CCR5 expressing MDSC subsets or Treg within live PBMC. *p < 0.05. 
 
4.3.4 Increased concentration of chronic inflammatory mediators in tumors  
Chronic inflammatory factors are involved in the activation, stimulation and recruitment of 
MDSC to the tumor microenvironment (Umansky and Sevko, 2013; Ugel et al., 2015; Arvelo 
et al., 2016). Therefore, we investigated such factors in the serum and tumor lysates of 
melanoma patients using bio-plex technique (Fig. 25). In all studied samples, CCL3, CCL4, 
CCL5, GM-CSF, VEGF, TNF-α, and IFN-γ displayed significantly higher concentrations in the 
tumor as compared to the serum.  
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Figure 25: Increased concentrations of chronic inflammatory factors for MDSC migration in skin 
tumors of melanoma patients of different stages. Inflammatory factors were measured in serum and 
skin metastasis lysates of 14 patients at different stages by bio-plex assay. Levels of CCL3, CCL4, 
CCL5, GM-CSF, VEGF, TNF-α and IFN-γ are expressed as pg/mg protein (A-G). *p < 0.05, **p < 0.01, 
***p < 0.001. 
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4.3.5 CCR5 is highly expressed on Treg 
Since we demonstrated that CCR5 is an important molecule on Treg in mice, we aimed to 
study its expression on Treg from the peripheral blood of melanoma patients with different 
stages. Fig. 26 shows a representative gating strategy of CCR5+ Treg from isolated PBMC of 
a melanoma patient at stage IV.  
First, singlets and live cells were gated. CD3 and CD4 double positive cells were identified. 
Out of these cells, CD127 negative cells were analyzed. To identify Treg, CD25 and FoxP3 
double positive cells were gated. Treg were characterized as CCR5+ or CCR5-, and the 
CD45RA and CD69 expression of the respective cell subset was analyzed. 
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Figure 26: Gating strategy of CD45RA-CCR5+CD4+Treg. 
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The frequency of Treg was assessed as the percentage of CD4+CD127-CD25+FoxP3- cells 
among total CD4+ T cells. We detected an increased frequency of circulating Treg in stage IV 
melanoma patients as compared to all other analyzed groups (Fig. 27A). Moreover, we 
assessed an increased frequency of CCR5 expressing Treg in melanoma patients as 
compared to HD (Fig. 27B). Furthermore, CCR5+ Treg were significantly increased in patients 
with advanced melanoma (stage IV) as compared to stage II patients and HD. In addition, we 
observed a significantly higher level of CCR5 expression on Treg in the group with all 
melanoma patients and in the group with melanoma patients stage I as compared to HD (Fig. 
27C). Interestingly, the frequency of antigen-experienced CD45RA-CCR5+ Treg in stage III 
was found to be increased as compared to stage I melanoma patients and HD (Fig. 27D). 
Furthermore, we demonstrated a slightly higher CCR5 expression on Treg in tumor tissue as 
compared to the peripheral blood (Fig. 27 E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results  70 
__________________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Evaluation of Treg in melanoma patients during tumor progression. PBMC from the 
peripheral blood of melanoma patients and HD were analyzed by flow cytometry. The frequency of CD4+ 
Treg in 66 melanoma patients of different stages and HD were assessed and the percentage of these 
cells within total CD4+ T cells is shown (A). CCR5 expression on CD4+ Treg was analyzed and the 
results of expression are presented as a frequency (B) and MFI (C). The frequency of CD45RA-CCR5+ 
Treg was assessed by flow cytometry and is shown as the percentage of CCR5+ Treg (D). PBMC and 
skin metastasis cells from stage III and IV melanoma patients were analyzed by flow cytometry. The 
frequency of CCR5 expression on Treg is shown (E). *p < 0.05, **p < 0.01. 
 
H
D al
l I II III IV H
D al
l I II III IV
Treg
H
D al
l I II III IV
0
5
10
15
*
*
*
*
 stage
CD45RA-
H
D al
l I II III IV
0
50
100
150
*
*
stage
%
 o
f 
C
C
R
5
+
 T
re
g
B C
D
A
E
Discussion  71 
__________________________________________________________________________ 
 
 
5 Discussion 
Malignant melanoma is the most aggressive form of human skin cancer with the highest 
morbidity (Nikolaou and Stratigos, 2014). Several standardized therapies to eliminate tumor 
cells are already in use like radiotherapy and chemotherapy. However, they are characterized 
by tumor relapse and therapeutic failure. In the last decades, a great attention was focused on 
tumor-infiltrating immune cells that have different roles in cancer. On one hand, they suppress 
tumor growth by eliminating tumor cells and on the other hand, they promote tumor progression 
and metastasis by inhibiting anti-tumor immune response (Bindea et al., 2014).  
 
5.1 Expression of CCR5 on murine MDSC 
During tumor development, a common mechanism to build up an immunosuppressive 
microenvironment is the dysregulation of myelopoiesis, which leads to the induction of MDSC 
(Ugel et al., 2015). The heterogeneous population of MDSC uses several mechanisms to 
suppress anti-tumor immunity. Each of these mechanisms suppresses the activation, 
proliferation, migration and effector function of T cells (Kumar et al., 2016). It was found that 
MDSC accumulate in the BM and spleen of tumor bearing mice (Gabrilovich and Nagaraj, 
2009; De Veirman et al., 2014). Previous results from our group revealed that MDSC 
accumulate during melanoma progression in ret transgenic mice (Meyer et al., 2011).  
Chemokines are responsible for accumulation of MDSC, in particular CCR5, so we focused on 
upregulation of CCR5 expression on MDSC. We hypothesize that CCR5 on MDSC might serve 
two distinct roles: 1) to induce MDSC migration from the BM to the site of the tumor; 2) to 
provide a strong immunosuppressive activity once pro-inflammatory factors are strongly 
secreted by the tumor. This would suggest a new therapeutic target for CCR5-CCR5 ligand 
axis in tumor therapy to regulate the anti-tumor immune response thus resulting in tumor 
regression.  
Accordingly, we found an increased frequency of CCR5 expressing MDSC in melanoma 
lesions of ret transgenic mice as compared to the periphery (the BM and peripheral blood) 
(Fig.3). The level of CCR5 expression was higher in skin tumors as compared to blood. CCR5+ 
MDSC accumulated during the course of melanoma progression in skin tumors and metastatic 
LN. Moreover, the CCR5 expression level increased during tumor development. Our data 
showed that CCR5+ Mo-MDSC and CCR5+ Gr-MDSC accumulated in melanoma lesions of ret 
transgenic mice and the level of CCR5 expression was higher in metastatic LN and skin tumors 
as compared to BM and peripheral blood (Fig. 4). In ret transgenic mice, the frequency of 
CCR5+ cells was higher among Gr-MDSC than among Mo-MDSC. The data suggests for the 
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first time, that CCR5 is important for the migration of MDSC to the site of the tumor and that 
tumors might secret factors leading to an upregulation of CCR5 expression in tumor-infiltrating 
MDSC and thus to the recruitment of these cells into the tumor microenvironment.  
To prove the second hypothesis, we analyzed the immunosuppressive phenotype of MDSC. 
We found that CCR5+ MDSC represented a higher production of NO and ROS, as well as an 
elevated expression of ARG-1 and PD-L1, than their CCR5- counterpart in melanoma lesions 
(Fig. 7). This was in agreement with a previous report, showing an increased NO production 
and ARG-1 expression on total MDSC (Meyer et al., 2011). Notably, we observed that the 
frequency of CCR5+ MDSC producing NO and ROS and expressing ARG-1 and PD-L1 
accumulated during tumor progression in ret transgenic mice (Fig. 8), reflecting their increased 
immunosuppressive function.  
We next analyzed the impact of CCR5 expression on the activation of MDSC. To this end, we 
stimulated CD8+ T cells isolated from the spleen of WT mice through the engagement of CD3 
and CD28 and co-cultured them with CCR5 MDSC subsets isolated from the BM of tumor 
bearing mice. Similar to the previous results (Meyer et al., 2011) that total MDSC from tumors 
of ret transgenic mice show inhibitory effects on T cell proliferation, we observed that both 
CCR5+ and CCR5- MDSC inhibited proliferation of stimulated T cells as compared to T cells 
cultured alone (Fig. 9B). Moreover, we detected a dose-dependent effect of MDSC on T cell 
proliferation. Comparing effects of BM-derived MDSC subsets, we found that CCR5+ MDSC 
exerted a tendency for stronger inhibition of T cell proliferation than their CCR5- counterparts 
(Fig. 9B).  
Taken together, we suggest that the upregulation of CCR5 expression on MDSC could regulate 
not only the migration of MDSC from the BM to the tumor but also their immunosuppressive 
phenotype during tumor progression. Our ex vivo data showed that CCR5+ MDSC displayed a 
stronger immunosuppressive phenotype than CCR5- cells indicated by increased NO and ROS 
production, as well as an elevated ARG-1 and PD-L1 expression. Moreover, we demonstrated 
that CCR5+ MDSC displayed only a slightly stronger capacity to suppress T cell proliferation 
than CCR5- cells. 
This apparent discrepancy between our data indicating a more immunosuppressive phenotype 
for CCR5+ MDSC and the results demonstrating only slightly increased immunosuppressive 
activity of CCR5+ MDSC might be due to the fact that we isolated CCR5+ MDSC from the BM 
and not from melanoma lesions, where they should have displayed stronger 
immunosuppressive activity than in the BM. This was due to the insufficient amounts of CCR5+ 
and CCR5- MDSC that could be isolated from skin tumors or metastatic LN. 
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5.2 Inflammatory factors in migration, accumulation and activity of MDSC 
We observed that the frequency of CCR5 expressing MDSC was increased and that the level 
of CCR5 expression was elevated with tumor load (indicator for tumor progression). This led 
to the suggestion that microenvironmental factors might induce CCR5 expression. We 
previously showed in ret transgenic mice that melanoma lesions contained increasingly high 
amounts of the inflammatory factors VEGF, IL-1β, IL-6 and TGF-β (Zhao et al., 2009). 
Furthermore, it was demonstrated that the concentration of pro-inflammatory cytokines like 
IFN-γ, IL-1β and GM-CSF was more elevated in quickly growing tumors than in slowly growing 
tumors (Meyer et al., 2011). In concordance with this data, we found an increased level of 
VEGF, TGF-β, CXCL10 and IL-6 in melanoma lesions of ret transgenic, tumor bearing mice 
as compared to serum (Fig. 5). Several recent studies reported that these factors might be a 
major inducer of MDSC (Umansky and Sevko, 2013; Stromnes et al., 2014; Ugel et al., 2015). 
It was shown that the reduction in the level of pro-inflammatory cytokines in the tumor 
microenvironment is associated with decreased frequency and activity of MDSC to suppress 
T cell proliferation in vitro (Sade-Feldman et al., 2013). It has been recently reported that an 
increased concentration of TNF-α induced CCL5 secretion is correlated with the 
aggressiveness of tumors in various mouse transplantable models (Katanov et al., 2015). In 
our study, we could not find an increased TNF-α level in melanoma lesions as compared to 
the serum, but found that the concentration of all three CCR5 ligands (CCL3, CCL4 and CCL5) 
were elevated in skin tumors (Fig. 5). The increased concentration of CCR5 ligands and the 
elevated frequency of CCR5+ cells in melanoma lesions led us to suggest that CCR5 ligands 
might be inducers for CCR5 expression on MDSC and that different chemokine signals might 
be important for the chemotaxis of MDSC from the BM to the tumor (Kitamura et al., 2015a). 
Consistent with this suggestion, in vitro studies showed that the migration, adhesion and 
differentiation of human monocytes are induced by CCL2, CXCL18 and CXCL12 respectively 
(Qian et al., 2011; Kitamura et al., 2015b). Therefore, we analyzed the CCR5 ligand-induced 
migration capacity of MDSC in vitro. The CCR5 ligands increased the percentage of migrated 
cells as compared to unstimulated MDSC. Furthermore, we found that the inhibition of CCR5 
ligands by mCCR5-Ig resulted in the reduced migration capacity of MDSC (Fig. 10). Thus, the 
inhibition of CCR5 ligands by mCCR5-Ig might be a novel target for immunotherapy to 
neutralize the tumor microenvironment.  
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5.3 Pattern of CCR5 expression on Treg and non-regulatory T cells in 
mice 
Murine models demonstrated that the frequency of Treg increases during tumor progression 
and the depletion or inhibition of Treg enhances anti-tumor immune response (Facciabene et 
al., 2012). The treatment of melanoma bearing mice with anti-CD25 monoclonal antibody 
depletes Treg and facilitates CD4+ T cell-mediated, anti-tumor immunity which results in a 
suppressed tumor growth (Jones et al., 2002). It was shown that the depletion of Treg leads 
to the complete regression of tumors (Li et al., 2010). Furthermore, the elimination of Treg 
results in the activation of CD8+ T cells and in an elevated level of these cells in the tumor. 
In our study, we found that CCR5 expression is not restricted to the immunosuppressive 
compartment of myeloid cells but also lymphocytes express CCR5. CCR5 expressing Treg 
were enriched in melanoma lesions of ret transgenic mice as compared to the peripheral blood, 
whereas only very few conventional CD4+ and CD8+ T cells from the metastatic LN and skin 
tumors expressed CCR5 (Fig. 12). Furthermore, the frequency of CCR5 expressing Treg was 
increased during course of melanoma development (Fig. 13). It was shown that Treg are 
recruited to the site of a tumor by CCL4 and CCL5 whereas CCR5 deficient mice show a 
reduced amount of Treg (Schlecker et al., 2012). Similar to our data, it was shown that Treg 
infiltrate into the tumor and that this infiltration is mediated by CCR5-CCR5 ligand interaction 
(Tan et al., 2009). They suggested that the blockage of this axis demonstrates a novel 
immunomodulatory strategy for the treatment of pancreatic adenocarcinoma. Interestingly, the 
disruption of the axis slows down the tumor growth although the migration of CD4+ T cells 
dropped only down of 20 %, mostly affecting Teff (Tan et al., 2009). Moreover, it was found 
that the CCR5-CCR5 ligand axis is important for Treg migration to the inflamed tissue (de 
Oliveira et al., 2014). We next analyzed Treg for their CD69 expression. CD69 is an activation 
marker, which is expressed on the surface of memory T cells and Treg (Radulovic and Niess, 
2015). We found an increased amount of CD69 expressing CCR5+ Treg in peripheral blood, 
spleen, metastatic LN and skin tumors as compared to CCR5- Treg (Fig. 13). Furthermore, the 
CD69 expression level was elevated in CCR5+ Treg.  
CCR5 might not only play a role in chemoattraction of leukocytes but also in T cell activation 
(Gonzalez-Martin et al., 2012). In CD4+ lymphocytes, CCR5 acts as a costimulatory receptor 
that does not play a role in the migration of these cells (Molon et al., 2005). It was found that 
CCR5 expression on CD8+ T cells is necessary for the tumor killing and for their migration to 
the site of tumor in a spontaneous breast cancer mouse model (Gonzalez-Martin et al., 2011). 
In our study, we found a low proportion of CD4+ and CD8+ T cells expressing CCR5 in 
melanoma lesions as compared to the spleen and peripheral blood (Fig. 14) leading to the 
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suggestion that CD4+ and CD8+ T cells may have other mechanisms involved in the migration 
of conventional T cell into the tumor microenvironment. One mechanism was proposed that 
CCR2-CCL2 interactions could be the major axis for the migration of CTL in colorectal 
carcinoma patients (Berencsi et al., 2011). Another study reported that CXCR3 ligands 
together with CCL5 favor T cell infiltration in cutaneous metastasis (Hong et al., 2011).  
We further assessed the frequency of melanoma-specific CCR5+CD8+ T cells by analyzing 
TRP-2 specific cells and found that these cells were elevated in the peripheral blood, spleen, 
metastatic LN and skin tumors as compared to their CCR5- counterpart. It was shown that the 
frequency of antigen-specific T cells was reduced in the peripheral blood of patients with 
advanced melanoma (Weide et al., 2014). Consistent with this information, we demonstrated 
in melanoma bearing mice that the frequency of TRP-2 specific CCR5+CD8+ T cells diminished 
during tumor development. 
Collectively, these observations suggest a crucial role for CCR5 expression on Treg in the 
migration to the site of tumors and in the immunosuppressive activity at the tumor 
microenvironment. Furthermore, the data imply that other pathways have to be involved in non-
regulatory T cell recruitment. 
 
5.4 The role of CCR5 on MDSC in melanoma patients 
In 1996, the CCR5∆32 mutation was discovered (Dean et al., 1996; Liu et al., 1996; Samson 
et al., 1996). The mutated CCR5 prevents cells of HIV envelope fusion (Barmania and Pepper, 
2013). It was found that high levels of CCR5 correlate with non-metastatic colorectal cancer, 
whereas low or deficient CCR5 expression correlate with an advanced form of disease 
(Zimmermann et al., 2010). Patients suffering from breast cancer with CCR5-∆32 had longer 
metastasis-free survival (Span et al., 2015).  
We assessed the distribution of MDSC subsets in the peripheral blood of melanoma patients 
of different stages and their counterparts in HD. Several studies demonstrated that the 
frequency of MDSC increases in the periphery of malignant melanoma patients and that this 
correlates with tumor burden (Filipazzi et al., 2012; Schilling et al., 2013). It was detected that 
the frequency of MDSC and Treg is elevated in the peripheral blood of melanoma patients as 
compared to HD (Jiang et al., 2015). Moreover, the increased frequency of MDSC is 
associated with a negative impact on survival. Monocytic MDSC expressing 
CD11b+CD33+CD14+HLA-DRlow were shown to be upregulated in stage I-IV melanoma 
patients (Rudolph et al., 2014). Similar to this data, we found an accumulation of monocytic 
MDSC (CD11b+HLD-DR-/lowCD14+CD15-) in melanoma patients as compared to IMC in HD.  
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We observed for the first time the CCR5 expression on human MDSC and found that the 
frequency of CCR5 expressing MDSC was higher in melanoma patients as compared to 
melanoma bearing mice indicating a more important role for CCR5 in a clinical situation. In a 
cohort of four patients, we found a significantly increased frequency of CCR5+ Mo-MDSC in 
metastatic melanoma as compared to the serum. We could not observe any significance for 
CCR5+ Gr-MDSC since the number of samples was low (Fig. 25). The proportion of MDSC in 
colorectal carcinoma was found to be correlated with modal metastasis, distant metastases 
and tumor stage (Sun et al., 2012). However, it has been reported that melanoma-infiltrating 
MDSC show an impaired ability to suppress T cell proliferation in vitro as compared to 
circulating MDSC (Gros et al., 2012). Analyzing the peripheral blood of melanoma patients, we 
demonstrated that the frequency of CCR5+ Mo-MDSC and CCR5+ Gr-MDSC was increased 
as compared to IMC in HD (Fig. 20). Furthermore, the level of CCR5 expression was higher in 
Mo-MDSC of melanoma patients as in IMC of HD. Thus it may lead to an enhanced MDSC 
accumulation and contribute to tumor-associated immune suppression.  
Analysis of the immunosuppressive phenotype of CCR5 expressing MDSC subsets revealed 
that circulating CCR5+ Mo-MDSC and CCR5+ Gr-MDSC from melanoma patients produce NO 
and ROS and express ARG-1 and PD-L1 during tumor development. The CCR5 expressing 
MDSC subsets are characterized by substantially elevated NO and ROS production, as well 
as ARG-1 and PD-L1 expression, as compared to CCR5- cells.  
Taken together, the results demonstrate that CCR5+ MDSC in melanoma patients show a 
similar immunosuppressive phenotype to that of mice, indicating that CCR5 not only plays a 
key role in the recruitment of human MDSC to the tumor microenvironment but also show that 
CCR5+ MDSC possess a stronger immunosuppressive phenotype as their CCR5- 
counterparts.  
 
5.5 Modulation of MDSC by chronic inflammatory factors in cancer 
patients 
It has been proposed that cytokine secretion by tumor cells increases the infiltrating immune 
cells in various cancer types to promote or suppress cancer progression according to the type 
of infiltrating cells (Koizumi et al., 2007). Since we already showed that CCR5+ Mo-MDSC 
accumulated in skin cancer as compared to serum, next we analyzed pro-inflammatory 
cytokines and chemokines in tumor samples and serum of melanoma patients. An increased 
concentration of IL-1β and IFN-γ in the serum of advanced melanoma patients as compared 
to HD has been described (Jiang et al., 2015). In our study, the levels of GM-CSF, VEGF, 
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TNF-α and IFN-γ were elevated in tumor samples of melanoma patients as compared to serum 
(Fig. 28). These observations create the conditions for MDSC accumulation and activity at the 
site of tumor. Similar to our results obtained in mice, we demonstrated an elevated 
concentration of CCR5 ligands CCL3, CCL4 and CCL5 in the tumor tissue as compared to the 
serum. Our observations are in agreement with a previous study showing that CCL5 is elevated 
in the serum of breast cancer patients and that CCL5 is overexpressed in colon cancer and 
metastasis as compared to healthy tissues (Cambien et al., 2011). Interestingly, hypoxia was 
found to promote an increased production of CCR5 and CCL5 in breast cancer cells (Lin et al., 
2012).  
Therefore, pro-inflammatory cytokines and CCR5 ligands might play a role in the recruitment 
of human MDSC from the peripheral blood to the tumor microenvironment and contribute to 
the tumor associated immune suppression.  
 
5.6 CCR5 expression on Treg in cancer patients 
It was demonstrated that Treg are present in the peripheral blood of cancer patients and that 
these cells are able to inhibit functions of other immune cells (Bergmann et al., 2008). 
Advanced stage melanoma patients are correlated with increased frequency of Treg indicating 
that melanoma promotes immunosuppressive Treg (McCarter et al., 2007; Jiang et al., 2015). 
The accumulation of Treg in the peripheral blood of melanoma patients is linked to poor 
prognosis. We demonstrated that the frequency of Treg increased in advanced stage 
melanoma patients (stage IV) as compared to early stage patients (stage I-III) and HD 
(Fig. 27), which was also showed by other authors (Woo et al., 2001; Strauss et al., 2007). 
We further observed an accumulation of CCR5+ Treg in patients stage IV as compared to early 
stage patients and HD. Moreover, the level of CCR5 expression on Treg was higher in 
melanoma patients as compared to HD. Furthermore, the frequency of antigen-experienced 
CCR5+ Treg, measured by CD45RA- expression, was elevated in advanced stage melanoma 
patients as compared to early stage patients and HD. In agreement with our data, it was found 
that the blockage of CCR5, CXCR3 and CXCR6 reduce Treg recruitment in the tumor 
microenvironment (Oldham et al., 2012). 
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5.7 The role of CCR5 in anti-cancer therapy 
We next asked if the inhibition of CCR5 ligands by mCCR5-Ig is relevant to the in vivo situation 
and if this might be a novel target for immunotherapy. It is known that the distribution of immune 
cells in cancer is controlled by soluble chemoattractants like chemokines that can modify 
myelopoiesis (Ugel et al., 2015). The blockage of CCL3 secretion from metastasis-associated 
macrophages was found to be a potential target for the treatment of metastatic breast cancer 
(Kitamura et al., 2015b). Furthermore, it has been shown that CCL2 induces macrophage 
recruitment in human breast cancer, suggesting that blocking CCL2 could help to inhibit  
macrophage migration (Ugel et al., 2015). However, a humanized monoclonal 
CCL2-neutralizing antibody (CNTO888) was ineffective to suppress serum CCL2 level since 
the feedback mechanisms promote CCL2 production (Sandhu et al., 2013).  
To this end, we studied the effect of mCCR5-Ig in ret transgenic, tumor bearing mice that binds 
and neutralizes all three CCR5 ligands (CCL3, CCL4 and CCL5) simultaneously. The fusion 
protein was previously described (Sapir et al., 2010). In a colon tumor model, the knockdown 
of CCL5 resulted in a reduce tumor growth in mice and decreased apoptosis of tumor-infiltrated 
CD8+ T cells. This indicates that CCL5 not only induced the migration of immunosuppressive 
cells to the tumor microenvironment, but also enhances their suppressive activity (Chang et 
al., 2012). In agreement with this observation, we found after mCCR5-Ig treatment 3 out of 7 
mice were still alive in the therapy group while all mice were dead in the control group (Fig. 
15). Furthermore, the frequency of MDSC were found to be decreased in the skin tumors after 
the treatment, suggesting that CCR5 have the capacity to induce the migration of these cells 
to melanoma lesions in ret transgenic mice (Fig. 16-17). We detected reduced production of 
NO by MDSC in the tumor of the mCCR5-Ig group as compared to the control group and to 
the BM. Interestingly, we found that not only CCR5+ MDSC but also CCR5+ Treg were reduced 
in the skin tumors of treated mice as compared to mice treated with anti-mouse IgG (control 
mice). Moreover, the frequency of these tumor-infiltrating cells was shown to be decreased 
during melanoma progression (Fig. 16-17). The activity of Treg, indicated by the expression of 
CD69, was reduced in the metastatic LN of the therapy group as compared to the control 
group. Moreover, the frequency of effector CD4+ and CD8+ T cells showed a tendency for 
increase in the tumors of mCCR5-Ig injected mice as compared to the control group (Fig. 17).  
A recent study indicated that CCR5 is expressed mostly on metastatic colorectal cancer cells 
and to some extent on lymphocytes and myeloid cells (Halama et al., 2016). They found that 
T cells in colorectal cancer invasive margins promote the growth and invasiveness of tumor 
cells by the secretion of CCL5. It was demonstrated that the blockage of CCR5 by maraviroc 
leads to an inhibition of tumor cells migration and induces tumor cell death in colon cancer 
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patients. CCL5/CCR3 axis was found to induce metastasis formation also in breast cancer 
(Velasco-Velazquez et al., 2014; Palucka and Coussens, 2016).  
Moreover, in a basal breast cancer model, CCR5 induced tumor cell invasiveness and 
metastasis (Velasco-Velazquez and Pestell, 2013), whereas the blockage of CCR5 by 
maraviroc or vicriviroc reduced metastasis (Velasco-Velazquez et al., 2012). Furthermore, 
maraviroc hampers the development of hepatocellular carcinoma (Ochoa-Callejero et al., 
2013) in mice and reduces pulmonary metastasis in mouse models of breast cancer (Velasco-
Velazquez et al., 2012) indicating that CCR5 antagonists can be used as a therapy to reduce 
the risk of metastasis in basal breast cancer patients.  
 
5.8 Conclusion 
Immunosuppressive cells like MDSC play a crucial role in the network that regulates anti-tumor 
immune response. Therefore, the exact mechanism for their migration and activation need to 
be elucidated. 
In this study, we discovered a new role for CCR5-CCR5 ligand interactions in the recruitment 
of immunosuppressive cells to the site of tumor. We found high levels of CCR5 ligands and 
pro-inflammatory mediators in melanoma lesions of ret transgenic mice and in skin metastasis 
of patients that were able to attract CCR5+ cells to the site of tumor. We demonstrated for the 
first time that CCR5 expression is elevated on MDSC, which was correlated with an increased 
immunosuppressive phenotype and an elevated activity of MDSC to inhibit anti-tumor immunity 
in a mouse melanoma model and melanoma patients. Moreover, the blockage of CCR5 ligands 
by mCCR5-Ig inhibited MDSC tumor-infiltration and restored CD4+ and CD8+ T cell 
accumulation in the tumor microenvironment. These results create a basis for the development 
of novel combinatory immunotherapeutic strategies for melanoma patients.  
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7 Abbreviation 
 
A  
APC allophycocyanin 
APC antigen-presenting cells 
ARG-1 arginase-1 
  
B  
BM bone marrow 
BSA bovine serum albumin 
  
C  
CCL C-C chemokine ligand 
CCR C-C chemokine receptor 
CD cluster of differentiation 
CTL cytotoxic lymphocytes 
CTLA-4 cytotoxic T lymphocyte antigen 4 
Cy cyanine 
  
D  
DC dendritic cells 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
  
E  
EDTA ethylene diamine-tetra-acetic acid 
et al. et alteri 
  
F  
FACS fluorescence activated cell sorting 
FBS fetal bovine serum 
FITC fluorescein-isothiocyanat 
FMO fluorescence minus one 
FoxP3 forkhead box P3 
FSC forward scatter 
  
G  
GM-CSF granulocyte-macrophage colony-stimulating factor 
  
H  
HLA-DR human leucocyte antigen-DR 
  
I  
IL interleukin 
IFN interferon 
iNOS inducible nitric oxide synthase 
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L  
LN lymph nodes 
  
M  
MACS magnetic-activated cell sorting 
MDSC myeloid-derived suppressor cells 
MHC major histocompatibility complex 
  
N  
NO nitric oxide 
Nf-κB nuclear factor-kappa B 
  
P  
PBMC peripheral blood mononuclear cells 
PBS phosphate buffered saline 
PD-1 programmed death 1 
PD-L1 programmed death ligand 1 
PE phycoerythrin 
PerCp peridinin-chlorophyll-protein complex 
PRR pattern recognition receptor 
  
R  
RBC red blood cell 
ret human ret proto-oncogene 
ROS reactive oxygen species 
rpm rounds per minute 
RPMI Roswell Park Memorial Institute medium 
RT room temperature 
  
S  
SSC side scatter 
  
T  
Tcon conventional CD4+ T cells (FoxP3-) 
TCR T cell receptor 
Teff effector T cells 
TGF-β transforming growth factor beta 
TIL tumor infiltrating lymphocytes 
TNF tumor necrosis factor 
Treg regulator CD4+ T cells (CD25+FoxP3+ ) 
TRP tyrosinase related protein 
  
V  
VEGF vascular endothelial growth factor 
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